{
    "abstract": "Background: Glucocorticoid drugs are highly effective anti-inflammatory agents, but chronic use is associated with extensive pharmacodynamic safety concerns that have a considerable negative impact on patient quality of life. Purpose: Vamorolone (VBP15) is a first-in-class steroidal multi-functional drug that shows potent inhibition of pro-inflammatory NFkB pathways via high-affinity binding to the glucocorticoid receptor, high affinity antagonism for the mineralocorticoid receptor, and membrane stabilization properties. Pre-clinical data in multiple mouse models of inflammation showed retention of anti-inflammatory efficacy, but loss of most or all side effects. Experimental approach: We report first-in-human Phase 1 clinical trials (86 healthy adult males), with single ascending doses (0.1\u201320.0 mg/kg), and multiple ascending doses (1.0\u201320 mg/kg/day; 14 days treatment). Key results: Vamorolone was well-tolerated at all dose levels. Vamorolone showed pharmacokinetic and metabolism profiles similar to prednisone. Biomarker studies showed loss of side effects of traditional glucocorticoid drugs (bone fragility, metabolic disturbance, immune suppression). Suppression of the adrenal axis was 10-fold less than prednisone. The crystallographic structure of vamorolone was solved, and compared to prednisone and dexamethasone. There was overlap in structure, but differences in conformation at the C-ring where glucocorticoids interact with Asn564 of the glucocorticoid receptor. The predicted loss of Asn564 binding to vamorolone may underlie the loss of gene transcriptional activity. Conclusions and interpretations: Vamorolone is a dissociative steroid that retains high affinity binding and nuclear translocation of both glucocorticoid (agonist) and mineralocorticoid (antagonist) receptors, but does not show pharmacodynamic safety concerns of existing glucocorticoid drugs at up to 20 mg/kg/day.",
    "author_highlights": [
        {
            "endOffset": 19338,
            "sentence": "Vamorolone (VBP15) is a steroidal drug that has shown dissociative properties.",
            "startOffset": 19260
        },
        {
            "endOffset": 19394,
            "sentence": "The X-ray crystal structure of vamorolone is presented.",
            "startOffset": 19339
        },
        {
            "endOffset": 19492,
            "sentence": "In a Phase 1 clinical trial in adult volunteers, vamorolone was shown to be safe to 20 mg/kg/day.",
            "startOffset": 19395
        },
        {
            "endOffset": 19584,
            "sentence": "Vamorolone showed no changes in bone turnover biomarkers, or markers of insulin resistance.",
            "startOffset": 19493
        },
        {
            "endOffset": 19648,
            "sentence": "Vamorolone showed no adrenal suppression through 3.0 mg/kg/day.",
            "startOffset": 19585
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "S. Stoney",
                    "initial": "S.S.",
                    "last": "Simons"
                },
                {
                    "first": "Dean P.",
                    "initial": "D.P.",
                    "last": "Edwards"
                },
                {
                    "first": "Raj",
                    "initial": "R.",
                    "last": "Kumar"
                }
            ],
            "doi": "10.1210/me.2013-1334",
            "firstpage": "173",
            "issn": "08888809",
            "lastpage": "182",
            "pmid": "24284822",
            "pub_year": 2014,
            "title": "Minireview: Dynamic structures of nuclear hormone receptors: New promises and challenges",
            "volume": "28"
        },
        "b0010": {
            "authors": [
                {
                    "first": "J\u00f3zsef",
                    "initial": "J.",
                    "last": "Haller"
                },
                {
                    "first": "\u00c9va",
                    "initial": "E.",
                    "last": "Mikics"
                },
                {
                    "first": "G\u00e1bor B.",
                    "initial": "G.B.",
                    "last": "Makara"
                }
            ],
            "doi": "10.1016/j.yfrne.2007.10.004",
            "firstpage": "273",
            "issn": "00913022",
            "lastpage": "291",
            "pmid": "18054070",
            "pub_year": 2008,
            "title": "The effects of non-genomic glucocorticoid mechanisms on bodily functions and the central neural system. A critical evaluation of findings",
            "volume": "29"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Turk",
                    "initial": "T.",
                    "last": "Rhen"
                },
                {
                    "first": "John A.",
                    "initial": "J.A.",
                    "last": "Cidlowski"
                }
            ],
            "doi": "10.1056/NEJMra050541",
            "firstpage": "1658",
            "issn": "00284793",
            "lastpage": "1723",
            "pmid": "16236742",
            "pub_year": 2005,
            "title": "Antiinflammatory action of glucocorticoids - New mechanisms for old drugs",
            "volume": "353"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Derek W.",
                    "initial": "D.W.",
                    "last": "Cain"
                },
                {
                    "first": "John A.",
                    "initial": "J.A.",
                    "last": "Cidlowski"
                }
            ],
            "doi": "10.1038/nri.2017.1",
            "firstpage": "233",
            "issn": "14741733",
            "lastpage": "247",
            "pmid": "28192415",
            "pub_year": 2017,
            "title": "Immune regulation by glucocorticoids",
            "volume": "17"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Eunkyung",
                    "initial": "E.",
                    "last": "Kauh"
                },
                {
                    "first": "Lori",
                    "initial": "L.",
                    "last": "Mixson"
                },
                {
                    "first": "Marie Pierre",
                    "initial": "M.P.",
                    "last": "Malice"
                },
                {
                    "first": "Sofie",
                    "initial": "S.",
                    "last": "Mesens"
                },
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Ramael"
                },
                {
                    "first": "Joanne",
                    "initial": "J.",
                    "last": "Burke"
                },
                {
                    "first": "Tom",
                    "initial": "T.",
                    "last": "Reynders"
                },
                {
                    "first": "Kristien",
                    "initial": "K.",
                    "last": "Van Dyck"
                },
                {
                    "first": "Chan",
                    "initial": "C.",
                    "last": "Beals"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Rosenberg"
                },
                {
                    "first": "Marcella",
                    "initial": "M.",
                    "last": "Ruddy"
                }
            ],
            "doi": "10.1530/EJE-11-0751",
            "firstpage": "459",
            "issn": "08044643",
            "lastpage": "467",
            "pmid": "22180452",
            "pub_year": 2012,
            "title": "Prednisone affects inflammation, glucose tolerance, and bone, turnover within hours of treatment in healthy individuals",
            "volume": "166"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Dona L.",
                    "initial": "D.L.",
                    "last": "Fleishaker"
                },
                {
                    "first": "Arnab",
                    "initial": "A.",
                    "last": "Mukherjee"
                },
                {
                    "first": "Fredrick S.",
                    "initial": "F.S.",
                    "last": "Whaley"
                },
                {
                    "first": "Shanthini",
                    "initial": "S.",
                    "last": "Daniel"
                },
                {
                    "first": "Bernhardt G.",
                    "initial": "B.G.",
                    "last": "Zeiher"
                }
            ],
            "doi": "10.1186/s12891-016-1135-3",
            "issn": "14712474",
            "pmid": "27424036",
            "pub_year": 2016,
            "title": "Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: A dose ranging, randomized, placebo-controlled, crossover study",
            "volume": "17"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Heike",
                    "initial": "H.",
                    "last": "Sch\u00e4cke"
                },
                {
                    "first": "Wolf Dietrich",
                    "initial": "W.D.",
                    "last": "D\u00f6cke"
                },
                {
                    "first": "Khusru",
                    "initial": "K.",
                    "last": "Asadullah"
                }
            ],
            "doi": "10.1016/S0163-7258(02)00297-8",
            "firstpage": "23",
            "issn": "01637258",
            "lastpage": "43",
            "pmid": "12441176",
            "pub_year": 2002,
            "title": "Mechanisms involved in the side effects of glucocorticoids",
            "volume": "96"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Graeff"
                },
                {
                    "first": "Fernando",
                    "initial": "F.",
                    "last": "Marin"
                },
                {
                    "first": "Helmut",
                    "initial": "H.",
                    "last": "Petto"
                },
                {
                    "first": "Ole",
                    "initial": "O.",
                    "last": "Kayser"
                },
                {
                    "first": "Andreas",
                    "initial": "A.",
                    "last": "Reisinger"
                },
                {
                    "first": "Jaime",
                    "initial": "J.",
                    "last": "Pe\u00f1a"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Zysset"
                },
                {
                    "first": "Claus Christian",
                    "initial": "C.C.",
                    "last": "Gl\u00fcer"
                }
            ],
            "doi": "10.1016/j.bone.2012.10.036",
            "firstpage": "568",
            "issn": "87563282",
            "lastpage": "577",
            "pmid": "23149277",
            "pub_year": 2013,
            "title": "High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA, reflects vertebral fracture status in men with glucocorticoid-induced osteoporosis",
            "volume": "52"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Lewis L.",
                    "initial": "L.L.",
                    "last": "Judd"
                },
                {
                    "first": "Pamela J.",
                    "initial": "P.J.",
                    "last": "Schettler"
                },
                {
                    "first": "E. Sherwood",
                    "initial": "E.S.",
                    "last": "Brown"
                },
                {
                    "first": "Owen M.",
                    "initial": "O.M.",
                    "last": "Wolkowitz"
                },
                {
                    "first": "Esther M.",
                    "initial": "E.M.",
                    "last": "Sternberg"
                },
                {
                    "first": "Bruce G.",
                    "initial": "B.G.",
                    "last": "Bender"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Bulloch"
                },
                {
                    "first": "John A.",
                    "initial": "J.A.",
                    "last": "Cidlowski"
                },
                {
                    "first": "E. Ronald",
                    "initial": "E.R.",
                    "last": "De Kloet"
                },
                {
                    "first": "Laurence",
                    "initial": "L.",
                    "last": "Fardet"
                },
                {
                    "first": "Marian",
                    "initial": "M.",
                    "last": "Jo\u00ebls"
                },
                {
                    "first": "Donald Y.M.",
                    "initial": "D.Y.M.",
                    "last": "Leung"
                },
                {
                    "first": "Bruce S.",
                    "initial": "B.S.",
                    "last": "McEwen"
                },
                {
                    "first": "Benno",
                    "initial": "B.",
                    "last": "Roozendaal"
                },
                {
                    "first": "Elisabeth F.C.",
                    "initial": "E.F.C.",
                    "last": "Van Rossum"
                },
                {
                    "first": "Junyoung",
                    "initial": "J.",
                    "last": "Ahn"
                },
                {
                    "first": "David W.",
                    "initial": "D.W.",
                    "last": "Brown"
                },
                {
                    "first": "Aaron",
                    "initial": "A.",
                    "last": "Plitt"
                },
                {
                    "first": "Gagandeep",
                    "initial": "G.",
                    "last": "Singh"
                }
            ],
            "doi": "10.1176/appi.ajp.2014.13091264",
            "firstpage": "1045",
            "issn": "0002953X",
            "lastpage": "1051",
            "pmid": "25272344",
            "pub_year": 2014,
            "title": "Adverse consequences of glucocorticoid medication: Psychological, cognitive, and behavioral effects",
            "volume": "171"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Marco",
                    "initial": "M.",
                    "last": "Sandri"
                },
                {
                    "first": "Claudia",
                    "initial": "C.",
                    "last": "Sandri"
                },
                {
                    "first": "Alex",
                    "initial": "A.",
                    "last": "Gilbert"
                },
                {
                    "first": "Carsten",
                    "initial": "C.",
                    "last": "Skurk"
                },
                {
                    "first": "Elisa",
                    "initial": "E.",
                    "last": "Calabria"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Picard"
                },
                {
                    "first": "Kenneth",
                    "initial": "K.",
                    "last": "Walsh"
                },
                {
                    "first": "Stefano",
                    "initial": "S.",
                    "last": "Schiaffino"
                },
                {
                    "first": "Stewart H.",
                    "initial": "S.H.",
                    "last": "Lecker"
                },
                {
                    "first": "Alfred L.",
                    "initial": "A.L.",
                    "last": "Goldberg"
                }
            ],
            "doi": "10.1016/S0092-8674(04)00400-3",
            "firstpage": "399",
            "issn": "00928674",
            "lastpage": "412",
            "pmid": "15109499",
            "pub_year": 2004,
            "title": "Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy",
            "volume": "117"
        },
        "b0055": {
            "authors": [
                {
                    "first": "George J.",
                    "initial": "G.J.",
                    "last": "Mangos"
                },
                {
                    "first": "Judith A.",
                    "initial": "J.A.",
                    "last": "Whitworth"
                },
                {
                    "first": "Paula M.",
                    "initial": "P.M.",
                    "last": "Williamson"
                },
                {
                    "first": "John J.",
                    "initial": "J.J.",
                    "last": "Kelly"
                }
            ],
            "doi": "10.1111/j.1440-1797.2003.00215.x",
            "firstpage": "267",
            "issn": "13205358",
            "lastpage": "273",
            "pmid": "15012696",
            "pub_year": 2003,
            "title": "Glucocorticoids and the kidney",
            "volume": "8"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Ellen B.",
                    "initial": "E.B.",
                    "last": "Goldbloom"
                },
                {
                    "first": "Arati",
                    "initial": "A.",
                    "last": "Mokashi"
                },
                {
                    "first": "Elizabeth A.",
                    "initial": "E.A.",
                    "last": "Cummings"
                },
                {
                    "first": "Sharon",
                    "initial": "S.",
                    "last": "Abish"
                },
                {
                    "first": "Susanne M.",
                    "initial": "S.M.",
                    "last": "Benseler"
                },
                {
                    "first": "Hien Q.",
                    "initial": "H.Q.",
                    "last": "Huynh"
                },
                {
                    "first": "Wade",
                    "initial": "W.",
                    "last": "Watson"
                },
                {
                    "first": "Alexandra",
                    "initial": "A.",
                    "last": "Ahmet"
                }
            ],
            "doi": "10.1136/archdischild-2016-311223",
            "firstpage": "340",
            "issn": "00039888",
            "lastpage": "345",
            "pmid": "28320817",
            "pub_year": 2017,
            "title": "Symptomatic adrenal suppression among children in Canada",
            "volume": "102"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Emira",
                    "initial": "E.",
                    "last": "Ayroldi"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Macchiarulo"
                },
                {
                    "first": "Carlo",
                    "initial": "C.",
                    "last": "Riccardi"
                }
            ],
            "doi": "10.1096/fj.14-254755",
            "firstpage": "5055",
            "issn": "08926638",
            "lastpage": "5070",
            "pmid": "25205742",
            "pub_year": 2014,
            "title": "Targeting glucocorticoid side effects: Selective glucocorticoid receptor modulator or glucocorticoid-induced leucine zipper? A perspective",
            "volume": "28"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Erica K.M.",
                    "initial": "E.K.M.",
                    "last": "Reeves"
                },
                {
                    "first": "Eric P.",
                    "initial": "E.P.",
                    "last": "Hoffman"
                },
                {
                    "first": "Kanneboyina",
                    "initial": "K.",
                    "last": "Nagaraju"
                },
                {
                    "first": "Jesse M.",
                    "initial": "J.M.",
                    "last": "Damsker"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "McCall"
                }
            ],
            "doi": "10.1016/j.bmc.2013.02.009",
            "firstpage": "2241",
            "issn": "09680896",
            "lastpage": "2249",
            "pmid": "23498916",
            "pub_year": 2013,
            "title": "VBP15: Preclinical characterization of a novel anti-inflammatory delta 9,11 steroid",
            "volume": "21"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Christopher R.",
                    "initial": "C.R.",
                    "last": "Heier"
                },
                {
                    "first": "Jesse M.",
                    "initial": "J.M.",
                    "last": "Damsker"
                },
                {
                    "first": "Qing",
                    "initial": "Q.",
                    "last": "Yu"
                },
                {
                    "first": "Blythe C.",
                    "initial": "B.C.",
                    "last": "Dillingham"
                },
                {
                    "first": "Tony",
                    "initial": "T.",
                    "last": "Huynh"
                },
                {
                    "first": "Jack H.",
                    "initial": "J.H.",
                    "last": "Van der Meulen"
                },
                {
                    "first": "Arpana",
                    "initial": "A.",
                    "last": "Sali"
                },
                {
                    "first": "Brittany K.",
                    "initial": "B.K.",
                    "last": "Miller"
                },
                {
                    "first": "Aditi",
                    "initial": "A.",
                    "last": "Phadke"
                },
                {
                    "first": "Luana",
                    "initial": "L.",
                    "last": "Scheffer"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Quinn"
                },
                {
                    "first": "Kathleen",
                    "initial": "K.",
                    "last": "Tatem"
                },
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Jordan"
                },
                {
                    "first": "Sherry",
                    "initial": "S.",
                    "last": "Dadgar"
                },
                {
                    "first": "Olga C.",
                    "initial": "O.C.",
                    "last": "Rodriguez"
                },
                {
                    "first": "Chris",
                    "initial": "C.",
                    "last": "Albanese"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Calhoun"
                },
                {
                    "first": "Heather",
                    "initial": "H.",
                    "last": "Gordish-Dressman"
                },
                {
                    "first": "Jyoti K.",
                    "initial": "J.K.",
                    "last": "Jaiswal"
                },
                {
                    "first": "Edward M.",
                    "initial": "E.M.",
                    "last": "Connor"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "Mccall"
                },
                {
                    "first": "Eric P.",
                    "initial": "E.P.",
                    "last": "Hoffman"
                },
                {
                    "first": "Erica K.M.",
                    "initial": "E.K.M.",
                    "last": "Reeves"
                },
                {
                    "first": "Kanneboyina",
                    "initial": "K.",
                    "last": "Nagaraju"
                }
            ],
            "doi": "10.1002/emmm.201302621",
            "firstpage": "1569",
            "issn": "17574676",
            "lastpage": "1585",
            "pmid": "24014378",
            "pub_year": 2013,
            "title": "VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects",
            "volume": "5"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Jesse M.",
                    "initial": "J.M.",
                    "last": "Damsker"
                },
                {
                    "first": "Blythe C.",
                    "initial": "B.C.",
                    "last": "Dillingham"
                },
                {
                    "first": "Mary C.",
                    "initial": "M.C.",
                    "last": "Rose"
                },
                {
                    "first": "Molly A.",
                    "initial": "M.A.",
                    "last": "Balsley"
                },
                {
                    "first": "Christopher R.",
                    "initial": "C.R.",
                    "last": "Heier"
                },
                {
                    "first": "Alan M.",
                    "initial": "A.M.",
                    "last": "Watson"
                },
                {
                    "first": "Erik J.",
                    "initial": "E.J.",
                    "last": "Stemmy"
                },
                {
                    "first": "Roslyn A.",
                    "initial": "R.A.",
                    "last": "Jurjus"
                },
                {
                    "first": "Tony",
                    "initial": "T.",
                    "last": "Huynh"
                },
                {
                    "first": "Kathleen",
                    "initial": "K.",
                    "last": "Tatem"
                },
                {
                    "first": "Kitipong",
                    "initial": "K.",
                    "last": "Uaesoontrachoon"
                },
                {
                    "first": "Dana M.",
                    "initial": "D.M.",
                    "last": "Berry"
                },
                {
                    "first": "Angela S.",
                    "initial": "A.S.",
                    "last": "Benton"
                },
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Freishtat"
                },
                {
                    "first": "Eric P.",
                    "initial": "E.P.",
                    "last": "Hoffman"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "McCall"
                },
                {
                    "first": "Heather",
                    "initial": "H.",
                    "last": "Gordish-Dressman"
                },
                {
                    "first": "Stephanie L.",
                    "initial": "S.L.",
                    "last": "Constant"
                },
                {
                    "first": "Erica K.M.",
                    "initial": "E.K.M.",
                    "last": "Reeves"
                },
                {
                    "first": "Kanneboyina",
                    "initial": "K.",
                    "last": "Nagaraju"
                }
            ],
            "doi": "10.1371/journal.pone.0063871",
            "issn": "19326203",
            "pmid": "23667681",
            "pub_year": 2013,
            "title": "VBP15, a Glucocorticoid Analogue, Is Effective at Reducing Allergic Lung Inflammation in Mice",
            "volume": "8"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Blythe C.",
                    "initial": "B.C.",
                    "last": "Dillingham"
                },
                {
                    "first": "Susan M.",
                    "initial": "S.M.",
                    "last": "Knoblach"
                },
                {
                    "first": "Gina M.",
                    "initial": "G.M.",
                    "last": "Many"
                },
                {
                    "first": "Brennan T.",
                    "initial": "B.T.",
                    "last": "Harmon"
                },
                {
                    "first": "Amanda M.",
                    "initial": "A.M.",
                    "last": "Mullen"
                },
                {
                    "first": "Christopher R.",
                    "initial": "C.R.",
                    "last": "Heier"
                },
                {
                    "first": "Luca",
                    "initial": "L.",
                    "last": "Bello"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "McCall"
                },
                {
                    "first": "Eric P.",
                    "initial": "E.P.",
                    "last": "Hoffman"
                },
                {
                    "first": "Edward M.",
                    "initial": "E.M.",
                    "last": "Connor"
                },
                {
                    "first": "Kanneboyina",
                    "initial": "K.",
                    "last": "Nagaraju"
                },
                {
                    "first": "Erica K.M.",
                    "initial": "E.K.M.",
                    "last": "Reeves"
                },
                {
                    "first": "Jesse M.",
                    "initial": "J.M.",
                    "last": "Damsker"
                }
            ],
            "doi": "10.1007/s10571-014-0133-y",
            "firstpage": "377",
            "issn": "02724340",
            "lastpage": "387",
            "pmid": "25392236",
            "pub_year": 2015,
            "title": "VBP15, a Novel Anti-Inflammatory, is Effective at Reducing the Severity of Murine Experimental Autoimmune Encephalomyelitis",
            "volume": "35"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Jesse M.",
                    "initial": "J.M.",
                    "last": "Damsker"
                },
                {
                    "first": "Laurie S.",
                    "initial": "L.S.",
                    "last": "Conklin"
                },
                {
                    "first": "Soheil",
                    "initial": "S.",
                    "last": "Sadri"
                },
                {
                    "first": "Blythe C.",
                    "initial": "B.C.",
                    "last": "Dillingham"
                },
                {
                    "first": "Karuna",
                    "initial": "K.",
                    "last": "Panchapakesan"
                },
                {
                    "first": "Christopher R.",
                    "initial": "C.R.",
                    "last": "Heier"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "McCall"
                },
                {
                    "first": "Anthony D.",
                    "initial": "A.D.",
                    "last": "Sandler"
                }
            ],
            "doi": "10.1007/s00011-016-0956-8",
            "firstpage": "737",
            "issn": "10233830",
            "lastpage": "743",
            "pmid": "27261270",
            "pub_year": 2016,
            "title": "VBP15, a novel dissociative steroid compound, reduces NF\u03baB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis",
            "volume": "65"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Lindsay M.",
                    "initial": "L.M.",
                    "last": "Garvin"
                },
                {
                    "first": "Yajun",
                    "initial": "Y.",
                    "last": "Chen"
                },
                {
                    "first": "Jesse M.",
                    "initial": "J.M.",
                    "last": "Damsker"
                },
                {
                    "first": "Mary C.",
                    "initial": "M.C.",
                    "last": "Rose"
                }
            ],
            "doi": "10.1016/j.pupt.2016.04.004",
            "firstpage": "17",
            "issn": "10945539",
            "lastpage": "26",
            "pmid": "27133900",
            "pub_year": 2016,
            "title": "A novel dissociative steroid VBP15 reduces MUC5AC gene expression in airway epithelial cells but lacks the GRE mediated transcriptional properties of dexamethasone",
            "volume": "38"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Subha V.",
                    "initial": "S.V.",
                    "last": "Raman"
                },
                {
                    "first": "Kan N.",
                    "initial": "K.N.",
                    "last": "Hor"
                },
                {
                    "first": "Wojciech",
                    "initial": "W.",
                    "last": "Mazur"
                },
                {
                    "first": "Nancy J.",
                    "initial": "N.J.",
                    "last": "Halnon"
                },
                {
                    "first": "John T.",
                    "initial": "J.T.",
                    "last": "Kissel"
                },
                {
                    "first": "Xin",
                    "initial": "X.",
                    "last": "He"
                },
                {
                    "first": "Tam",
                    "initial": "T.",
                    "last": "Tran"
                },
                {
                    "first": "Suzanne",
                    "initial": "S.",
                    "last": "Smart"
                },
                {
                    "first": "Beth",
                    "initial": "B.",
                    "last": "McCarthy"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Taylor"
                },
                {
                    "first": "John L.",
                    "initial": "J.L.",
                    "last": "Jefferies"
                },
                {
                    "first": "Jill A.",
                    "initial": "J.A.",
                    "last": "Rafael-Fortney"
                },
                {
                    "first": "Jeovanna",
                    "initial": "J.",
                    "last": "Lowe"
                },
                {
                    "first": "Sharon L.",
                    "initial": "S.L.",
                    "last": "Roble"
                },
                {
                    "first": "Linda H.",
                    "initial": "L.H.",
                    "last": "Cripe"
                }
            ],
            "doi": "10.1016/S1474-4422(14)70318-7",
            "firstpage": "153",
            "issn": "14744422",
            "lastpage": "161",
            "pmid": "25554404",
            "pub_year": 2015,
            "title": "Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: A randomised, double-blind, placebo-controlled trial",
            "volume": "14"
        },
        "b0105": {
            "authors": [
                {
                    "first": "R. J.",
                    "initial": "R.J.",
                    "last": "Freishtat"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Nino"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Tsegaye"
                },
                {
                    "first": "S. E.",
                    "initial": "S.E.",
                    "last": "Alcala"
                },
                {
                    "first": "A. S.",
                    "initial": "A.S.",
                    "last": "Benton"
                },
                {
                    "first": "A. M.",
                    "initial": "A.M.",
                    "last": "Watson"
                },
                {
                    "first": "E. K.M.",
                    "initial": "E.K.M.",
                    "last": "Reeves"
                },
                {
                    "first": "S. K.",
                    "initial": "S.K.",
                    "last": "Haider"
                },
                {
                    "first": "J. M.",
                    "initial": "J.M.",
                    "last": "Damsker"
                }
            ],
            "doi": "10.1186/s12931-015-0293-4",
            "issn": "14659921",
            "pmid": "26511361",
            "pub_year": 2015,
            "title": "Pharmacologically-induced mitotic synchrony in airway epithelial cells as a mechanism of action of anti-inflammatory drugs",
            "volume": "16"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Sarah E.",
                    "initial": "S.E.",
                    "last": "Alcala"
                },
                {
                    "first": "Angela S.",
                    "initial": "A.S.",
                    "last": "Benton"
                },
                {
                    "first": "Alan M.",
                    "initial": "A.M.",
                    "last": "Watson"
                },
                {
                    "first": "Suraiya",
                    "initial": "S.",
                    "last": "Kureshi"
                },
                {
                    "first": "Erica M.K.",
                    "initial": "E.M.K.",
                    "last": "Reeves"
                },
                {
                    "first": "Jesse",
                    "initial": "J.",
                    "last": "Damsker"
                },
                {
                    "first": "Zuyi",
                    "initial": "Z.",
                    "last": "Wang"
                },
                {
                    "first": "Kanneboyina",
                    "initial": "K.",
                    "last": "Nagaraju"
                },
                {
                    "first": "Julia",
                    "initial": "J.",
                    "last": "Anderson"
                },
                {
                    "first": "Aaron M.",
                    "initial": "A.M.",
                    "last": "Williams"
                },
                {
                    "first": "Amber J.Y.",
                    "initial": "A.J.Y.",
                    "last": "Lee"
                },
                {
                    "first": "Kathleen",
                    "initial": "K.",
                    "last": "Hayes"
                },
                {
                    "first": "Mary C.",
                    "initial": "M.C.",
                    "last": "Rose"
                },
                {
                    "first": "Eric P.",
                    "initial": "E.P.",
                    "last": "Hoffman"
                },
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Freishtat"
                }
            ],
            "doi": "10.1165/rcmb.2013-0396OC",
            "firstpage": "363",
            "issn": "10441549",
            "lastpage": "369",
            "pmid": "24669775",
            "pub_year": 2014,
            "title": "Mitotic asynchrony induces transforming growth factor-\u03b21 secretion from airway epithelium",
            "volume": "51"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Sherry",
                    "initial": "S.",
                    "last": "Dadgar"
                },
                {
                    "first": "Zuyi",
                    "initial": "Z.",
                    "last": "Wang"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Johnston"
                },
                {
                    "first": "Akanchha",
                    "initial": "A.",
                    "last": "Kesari"
                },
                {
                    "first": "Kanneboyina",
                    "initial": "K.",
                    "last": "Nagaraju"
                },
                {
                    "first": "Yi Wen",
                    "initial": "Y.W.",
                    "last": "Chen"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Ashley Hill"
                },
                {
                    "first": "Terence A.",
                    "initial": "T.A.",
                    "last": "Partridge"
                },
                {
                    "first": "Mamta",
                    "initial": "M.",
                    "last": "Giri"
                },
                {
                    "first": "Robert J.",
                    "initial": "R.J.",
                    "last": "Freishtat"
                },
                {
                    "first": "Javad",
                    "initial": "J.",
                    "last": "Nazarian"
                },
                {
                    "first": "Jianhua",
                    "initial": "J.",
                    "last": "Xuan"
                },
                {
                    "first": "Yue",
                    "initial": "Y.",
                    "last": "Wang"
                },
                {
                    "first": "Eric P.",
                    "initial": "E.P.",
                    "last": "Hoffman"
                }
            ],
            "doi": "10.1083/jcb.201402079",
            "firstpage": "139",
            "issn": "00219525",
            "lastpage": "158",
            "pmid": "25313409",
            "pub_year": 2014,
            "title": "Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy",
            "volume": "207"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Bonnie W.",
                    "initial": "B.W.",
                    "last": "Ramsey"
                },
                {
                    "first": "Gerald T.",
                    "initial": "G.T.",
                    "last": "Nepom"
                },
                {
                    "first": "Sagar",
                    "initial": "S.",
                    "last": "Lonial"
                }
            ],
            "doi": "10.1056/NEJMra1612575",
            "firstpage": "1762",
            "issn": "00284793",
            "lastpage": "1769",
            "pmid": "28467868",
            "pub_year": 2017,
            "title": "Academic, foundation, and industry collaboration in finding new therapies",
            "volume": "376"
        },
        "b0125": {
            "authors": [
                {
                    "first": "George M.",
                    "initial": "G.M.",
                    "last": "Sheldrick"
                }
            ],
            "doi": "10.1107/S2053229614024218",
            "firstpage": "3",
            "issn": "20532296",
            "lastpage": "8",
            "pub_year": 2015,
            "title": "Crystal structure refinement with SHELXL",
            "volume": "71"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Yetrib",
                    "initial": "Y.",
                    "last": "Hathout"
                },
                {
                    "first": "Laurie S.",
                    "initial": "L.S.",
                    "last": "Conklin"
                },
                {
                    "first": "Haeri",
                    "initial": "H.",
                    "last": "Seol"
                },
                {
                    "first": "Heather",
                    "initial": "H.",
                    "last": "Gordish-Dressman"
                },
                {
                    "first": "Kristy J.",
                    "initial": "K.J.",
                    "last": "Brown"
                },
                {
                    "first": "Lauren P.",
                    "initial": "L.P.",
                    "last": "Morgenroth"
                },
                {
                    "first": "Kanneboyina",
                    "initial": "K.",
                    "last": "Nagaraju"
                },
                {
                    "first": "Christopher R.",
                    "initial": "C.R.",
                    "last": "Heier"
                },
                {
                    "first": "Jesse M.",
                    "initial": "J.M.",
                    "last": "Damsker"
                },
                {
                    "first": "John N.",
                    "initial": "J.N.",
                    "last": "Van Den Anker"
                },
                {
                    "first": "Erik",
                    "initial": "E.",
                    "last": "Henricson"
                },
                {
                    "first": "Paula R.",
                    "initial": "P.R.",
                    "last": "Clemens"
                },
                {
                    "first": "Jean K.",
                    "initial": "J.K.",
                    "last": "Mah"
                },
                {
                    "first": "Craig",
                    "initial": "C.",
                    "last": "McDonald"
                },
                {
                    "first": "Eric P.",
                    "initial": "E.P.",
                    "last": "Hoffman"
                }
            ],
            "doi": "10.1038/srep31727",
            "issn": "20452322",
            "pmid": "27530235",
            "pub_year": 2016,
            "title": "Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children",
            "volume": "6"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Alex",
                    "initial": "A.",
                    "last": "Rafacho"
                },
                {
                    "first": "Henrik",
                    "initial": "H.",
                    "last": "Orts\u00e4ter"
                },
                {
                    "first": "Angel",
                    "initial": "A.",
                    "last": "Nadal"
                },
                {
                    "first": "Ivan",
                    "initial": "I.",
                    "last": "Quesada"
                }
            ],
            "doi": "10.1530/JOE-14-0373",
            "firstpage": "R49",
            "issn": "00220795",
            "lastpage": "R62",
            "pmid": "25271217",
            "pub_year": 2014,
            "title": "Glucocorticoid treatment and endocrine pancreas function: Implications for glucose homeostasis, insulin resistance and diabetes",
            "volume": "223"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Mohamed",
                    "initial": "M.",
                    "last": "Younes"
                },
                {
                    "first": "Fadoua",
                    "initial": "F.",
                    "last": "Neffati"
                },
                {
                    "first": "Mongi",
                    "initial": "M.",
                    "last": "Touzi"
                },
                {
                    "first": "Saoussen",
                    "initial": "S.",
                    "last": "Hassen-Zrour"
                },
                {
                    "first": "Yosr",
                    "initial": "Y.",
                    "last": "Fendri"
                },
                {
                    "first": "Ismail",
                    "initial": "I.",
                    "last": "B\u00e9jia"
                },
                {
                    "first": "Adel",
                    "initial": "A.",
                    "last": "Ben Amor"
                },
                {
                    "first": "Naceur",
                    "initial": "N.",
                    "last": "Bergaoui"
                },
                {
                    "first": "Mohamed Fadhel",
                    "initial": "M.F.",
                    "last": "Najjar"
                }
            ],
            "doi": "10.1016/j.jbspin.2006.10.009",
            "firstpage": "472",
            "issn": "1297319X",
            "lastpage": "476",
            "pmid": "17919959",
            "pub_year": 2007,
            "title": "Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and non-diabetic patients",
            "volume": "74"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Holger",
                    "initial": "H.",
                    "last": "Henneicke"
                },
                {
                    "first": "Sylvia J.",
                    "initial": "S.J.",
                    "last": "Gasparini"
                },
                {
                    "first": "Tara C.",
                    "initial": "T.C.",
                    "last": "Brennan-Speranza"
                },
                {
                    "first": "Hong",
                    "initial": "H.",
                    "last": "Zhou"
                },
                {
                    "first": "Markus J.",
                    "initial": "M.J.",
                    "last": "Seibel"
                }
            ],
            "doi": "10.1016/j.tem.2013.12.006",
            "firstpage": "197",
            "issn": "10432760",
            "lastpage": "211",
            "pmid": "24418120",
            "pub_year": 2014,
            "title": "Glucocorticoids and bone: Local effects and systemic implications",
            "volume": "25"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Mark S.",
                    "initial": "M.S.",
                    "last": "Cooper"
                },
                {
                    "first": "Markus J.",
                    "initial": "M.J.",
                    "last": "Seibel"
                },
                {
                    "first": "Hong",
                    "initial": "H.",
                    "last": "Zhou"
                }
            ],
            "doi": "10.1016/j.bone.2015.05.038",
            "firstpage": "64",
            "issn": "87563282",
            "lastpage": "68",
            "pmid": "26051468",
            "pub_year": 2016,
            "title": "Glucocorticoids, bone and energy metabolism",
            "volume": "82"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Robert I.",
                    "initial": "R.I.",
                    "last": "Scheinman"
                },
                {
                    "first": "Patricia C.",
                    "initial": "P.C.",
                    "last": "Cogswell"
                },
                {
                    "first": "Alan K.",
                    "initial": "A.K.",
                    "last": "Lofquist"
                },
                {
                    "first": "Albert S.",
                    "initial": "A.S.",
                    "last": "Baldwin"
                }
            ],
            "doi": "10.1126/science.270.5234.283",
            "firstpage": "283",
            "issn": "00368075",
            "lastpage": "286",
            "pmid": "7569975",
            "pub_year": 1995,
            "title": "Role of transcriptional activation of I\u03baB\u03b1 in mediation of immunosuppression by glucocorticoids",
            "volume": "270"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Viktor",
                    "initial": "V.",
                    "last": "Suitchmezian"
                },
                {
                    "first": "Inke",
                    "initial": "I.",
                    "last": "Jess"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Sehnert"
                },
                {
                    "first": "Lena",
                    "initial": "L.",
                    "last": "Seyfarth"
                },
                {
                    "first": "J\u00fcrgen",
                    "initial": "J.",
                    "last": "Senker"
                },
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "N\u00e4ther"
                }
            ],
            "doi": "10.1021/cg700866f",
            "firstpage": "98",
            "issn": "15287483",
            "lastpage": "107",
            "pub_year": 2008,
            "title": "Structural, thermodynamic, and kinetic aspects of the polymorphism and pseudopolymorphism of prednisolone (11,17\u03b1,21-trihydroxy-1,4-pregnadien-3, 20-dion)",
            "volume": "8"
        },
        "b0165": {
            "authors": [
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Ma"
                },
                {
                    "first": "H. J.",
                    "initial": "H.J.",
                    "last": "McMillan"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Karag\u00fczel"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Goodin"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Wasson"
                },
                {
                    "first": "M. A.",
                    "initial": "M.A.",
                    "last": "Matzinger"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "DesClouds"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Cram"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Page"
                },
                {
                    "first": "V. N.",
                    "initial": "V.N.",
                    "last": "Konji"
                },
                {
                    "first": "B.",
                    "initial": "B.",
                    "last": "Lentle"
                },
                {
                    "first": "L. M.",
                    "initial": "L.M.",
                    "last": "Ward"
                }
            ],
            "doi": "10.1007/s00198-016-3774-5",
            "firstpage": "597",
            "issn": "0937941X",
            "lastpage": "608",
            "pmid": "27774565",
            "pub_year": 2017,
            "title": "The time to and determinants of first fractures in boys with Duchenne muscular dystrophy",
            "volume": "28"
        },
        "b0170": {
            "authors": [
                {
                    "first": "Jennifer M.",
                    "initial": "J.M.",
                    "last": "Bell"
                },
                {
                    "first": "Bronagh",
                    "initial": "B.",
                    "last": "Blackwood"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Shields"
                },
                {
                    "first": "Janet",
                    "initial": "J.",
                    "last": "Watters"
                },
                {
                    "first": "Alistair",
                    "initial": "A.",
                    "last": "Hamilton"
                },
                {
                    "first": "Timothy",
                    "initial": "T.",
                    "last": "Beringer"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Elliott"
                },
                {
                    "first": "Rosaline",
                    "initial": "R.",
                    "last": "Quinlivan"
                },
                {
                    "first": "Sandya",
                    "initial": "S.",
                    "last": "Tirupathi"
                }
            ],
            "doi": "10.1002/14651858.CD010899",
            "issn": "1469493X",
            "pub_year": 2014,
            "title": "Interventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophy",
            "volume": "2014"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Stefanie",
                    "initial": "S.",
                    "last": "Hammer"
                },
                {
                    "first": "Irina",
                    "initial": "I.",
                    "last": "Spika"
                },
                {
                    "first": "Wolfgang",
                    "initial": "W.",
                    "last": "Sippl"
                },
                {
                    "first": "Gisela",
                    "initial": "G.",
                    "last": "Jessen"
                },
                {
                    "first": "Burkhard",
                    "initial": "B.",
                    "last": "Kleuser"
                },
                {
                    "first": "Hans Dieter",
                    "initial": "H.D.",
                    "last": "H\u00f6ltje"
                },
                {
                    "first": "Monika",
                    "initial": "M.",
                    "last": "Sch\u00e4fer-Korting"
                }
            ],
            "doi": "10.1016/S0039-128X(03)00030-8",
            "firstpage": "329",
            "issn": "0039128X",
            "lastpage": "339",
            "pmid": "12787894",
            "pub_year": 2003,
            "title": "Glucocorticoid receptor interactions with glucocorticoids: Evaluation by molecular modeling and functional analysis of glucocorticoid receptor mutants",
            "volume": "68"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Jessica A.",
                    "initial": "J.A.",
                    "last": "Chadwick"
                },
                {
                    "first": "Sayak",
                    "initial": "S.",
                    "last": "Bhattacharya"
                },
                {
                    "first": "Jeovanna",
                    "initial": "J.",
                    "last": "Lowe"
                },
                {
                    "first": "Noah",
                    "initial": "N.",
                    "last": "Weisleder"
                },
                {
                    "first": "Jill A.",
                    "initial": "J.A.",
                    "last": "Rafael-Fortney"
                }
            ],
            "doi": "10.1152/ajpcell.00269.2016",
            "firstpage": "C155",
            "issn": "03636143",
            "lastpage": "C168",
            "pmid": "27881412",
            "pub_year": 2017,
            "title": "Renin-angiotensin-aldosterone system inhibitors improve membrane stability and change gene-expression profiles in dystrophic skeletal muscles",
            "volume": "312"
        },
        "b0185": null
    },
    "body_text": [
        {
            "endOffset": 48270,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "At 20.0 mg/kg/day, 4 of 6 showed adrenal suppression after a single dose, and all subjects (5/5) after two weeks of dosing.",
            "startOffset": 48147,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 32590,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A total of 32 male subjects between 18 and 45 years of age, with a BMI range of 19.6 to 30.3 kg/m2, and no females participated in the MAD part.",
            "startOffset": 32446,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 31290,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "All 42 subjects who received vamorolone comprised the SAD PK analysis population.",
            "startOffset": 31209,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 62307,
            "parents": [],
            "secId": "s0095",
            "sentence": "Using multiple serum biomarkers bridged to later clinical safety concerns, we have shown that vamorolone has lost key safety concerns regarding bone turnover, insulin resistance, and immunosuppression.",
            "startOffset": 62106,
            "title": "Discussion"
        },
        {
            "endOffset": 63326,
            "parents": [],
            "secId": "s0095",
            "sentence": "Phase 2 trials of vamorolone in DMD are planned to go to 10-times prednisone dose.",
            "startOffset": 63244,
            "title": "Discussion"
        },
        {
            "endOffset": 29002,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 29001,
                    "startOffset": 28997
                }
            },
            "secId": "s0005",
            "sentence": "Vamorolone retains or improves this cell and tissue synchrony activity of glucocorticoids [23].",
            "startOffset": 28907,
            "title": "Introduction"
        },
        {
            "endOffset": 50625,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0070",
            "sentence": "This indicates that vamorolone has lost the metabolic side effect of insulin resistance through 20 mg/kg/day.",
            "startOffset": 50516,
            "title": "Insulin resistance"
        },
        {
            "endOffset": 53989,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "b0160": {
                    "endOffset": 53979,
                    "startOffset": 53975
                }
            },
            "secId": "s0090",
            "sentence": "The crystal structure of vamorolone was overlaid to previously reported crystal structures of prednisone and dexamethasone [32] (Fig. 6).",
            "startOffset": 53852,
            "title": "X-ray structure determination for vamorolone and comparison to glucocorticoids"
        },
        {
            "endOffset": 28060,
            "parents": [],
            "secId": "s0005",
            "sentence": "We used in vitro reporter assays for multiple steroid hormone receptors, in both agonist and antagonist modes, and showed that vamorolone is a potent antagonist for the mineralocorticoid receptor, in contrast to the agonist activity of glucocorticoids (unpublished observations).",
            "startOffset": 27781,
            "title": "Introduction"
        },
        {
            "endOffset": 43446,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The geometric mean t\u00bd range was somewhat longer at the higher doses, due primarily to vamorolone being quantifiable in plasma for a longer duration in the higher dose groups (e.g. above limits of detection) (Table 1).",
            "startOffset": 43229,
            "title": "Pharmacokinetics: Single ascending dose"
        },
        {
            "endOffset": 50254,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "refoffsets": {
                "b0140": {
                    "endOffset": 50253,
                    "startOffset": 50249
                }
            },
            "secId": "s0070",
            "sentence": "Hyperglycemia and hyperinsulinemia are also seen 24 h after a single 2.0 mg/kg dose of prednisone [28].",
            "startOffset": 50151,
            "title": "Insulin resistance"
        },
        {
            "endOffset": 41061,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "All biomarkers were analyzed using standard immunoassays by PRA.",
            "startOffset": 40997,
            "title": "Biomarker methods"
        },
        {
            "endOffset": 36626,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "Once the sentinel group demonstrated that the dose was generally safe and well tolerated, based on a review of sentinel safety and tolerability data (including reported AEs, clinical laboratory tests, vital signs, and ECGs) after QD dosing for 4 days, dosing in the sentinel group continued, and the remaining 5 subjects were randomized to receive vamorolone or placebo in a 4:1 ratio and dosed QD for 14 days.",
            "startOffset": 36216,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 41747,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Analytical numeric absorption correction using a multifaceted crystal model was applied using CrysAlisPro.",
            "startOffset": 41641,
            "title": "Single crystal X-ray crystallography"
        },
        {
            "endOffset": 23079,
            "parents": [],
            "secId": "s0005",
            "sentence": "Some of the most widely prescribed drugs target these receptors or their synthetic pathways, including prednisone, statins, bisphosphonates, and many others.",
            "startOffset": 22922,
            "title": "Introduction"
        },
        {
            "endOffset": 53054,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "The human NOAEL was determined by the Phase 1 study director to be 20 mg/kg/day, the highest dose tested.",
            "startOffset": 52949,
            "title": "Clinical safety findings in the Phase 1 trials"
        },
        {
            "endOffset": 42636,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Eight adult male volunteers were studied in each dose group (6 drug-treated, 2 placebo).",
            "startOffset": 42548,
            "title": "Pharmacokinetics: Single ascending dose"
        },
        {
            "endOffset": 31208,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "All 54 subjects in the SAD part and 32 in the MAD part received at least one dose of vamorolone or placebo and were included in the safety population.",
            "startOffset": 31058,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 49695,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "Thus, for acute measures of adrenal suppression 24 h after the first dose, there was approximately a 10-fold difference in potency (prednisone > vamorolone).",
            "startOffset": 49538,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 54823,
            "parents": [],
            "secId": "s0095",
            "sentence": "Vamorolone is a steroid with very poor solubility in aqueous solutions, similar to traditional glucocorticoids and cortisol.",
            "startOffset": 54699,
            "title": "Discussion"
        },
        {
            "endOffset": 36215,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "In each cohort, 3 sentinel subjects were administered vamorolone or placebo, in a 2:1 ratio.",
            "startOffset": 36123,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 24647,
            "parents": [],
            "secId": "s0005",
            "sentence": "Aldosterone typically circulates at much lower concentrations than cortisol, but aldosterone-responsive cells express high levels of 11\u03b2-Hydroxysteroid dehydrogenase (11BHSD) isoforms, leading to inactivation of cortisol to cortisone.",
            "startOffset": 24413,
            "title": "Introduction"
        },
        {
            "endOffset": 41864,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The temperature of the data collection was controlled using the system Cryojet (manufactured by Oxford Instruments).",
            "startOffset": 41748,
            "title": "Single crystal X-ray crystallography"
        },
        {
            "endOffset": 52454,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0080",
            "sentence": "This suggests that vamorolone has lost the safety concern of immune suppression.",
            "startOffset": 52374,
            "title": "Immune suppression"
        },
        {
            "endOffset": 57253,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 57252,
                    "startOffset": 57242
                },
                "b0075": {
                    "endOffset": 57252,
                    "startOffset": 57242
                },
                "b0095": {
                    "endOffset": 57252,
                    "startOffset": 57242
                }
            },
            "secId": "s0095",
            "sentence": "Adrenal suppression was studied using in vitro assays in multiple cells types, and vamorolone consistently showed about \u223c1% of the adrenal suppressive activity of traditional glucocorticoids [14,15,19].",
            "startOffset": 57051,
            "title": "Discussion"
        },
        {
            "endOffset": 42547,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Doses were then escalated by 3-fold increments for 6 dose groups (0.1, 0.3, 1.0, 3.0, 9.0, 20.0 mg/kg).",
            "startOffset": 42444,
            "title": "Pharmacokinetics: Single ascending dose"
        },
        {
            "endOffset": 49138,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "At 24 h after the initial dose, reductions in morning cortisol 24 h later were seen in the 20 mg (0.25 mg/kg) (9 \u00b5g/dL cortisol), 40 mg (0.5 mg/kg) (7 \u00b5g/dL cortisol), and 60 mg (0.75 mg/kg) (6 \u00b5g/dL cortisol).",
            "startOffset": 48928,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 60362,
            "parents": [],
            "secId": "s0095",
            "sentence": "Metabolic derangement is pervasive, with rapid and profound induction of insulin resistance, weight gain, and Cushingoid appearance.",
            "startOffset": 60230,
            "title": "Discussion"
        },
        {
            "endOffset": 23984,
            "parents": [],
            "secId": "s0005",
            "sentence": "In the late 1940\u2032s, cortisol, the adrenal steroid hormone responsible for circadian rhythms and stress response, was found to show strong anti-inflammatory effects in arthritis patients, leading to the Nobel Prize in 1950.",
            "startOffset": 23762,
            "title": "Introduction"
        },
        {
            "endOffset": 38597,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "An MTD was not reached during MAD dosing, and all 4 planned doses were administered.",
            "startOffset": 38513,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 42847,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "There were dose-related increases in the mean vamorolone plasma concentrations and dose-related pharmacokinetic (PK) parameter values after administration of single 0.1 mg/kg to 20 mg/kg doses (Fig. 1, Table 1).",
            "startOffset": 42636,
            "title": "Pharmacokinetics: Single ascending dose"
        },
        {
            "endOffset": 50361,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0070",
            "sentence": "Fasting insulin and glucose levels were assessed in all dose groups in the vamorolone Phase 1 SAD and MAD.",
            "startOffset": 50255,
            "title": "Insulin resistance"
        },
        {
            "endOffset": 50515,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0070",
            "sentence": "Levels did not differ from placebo for any dose group at any time point and were within normal ranges (Supplemental Fig. 1; Supplemental Tables 1 and 2).",
            "startOffset": 50362,
            "title": "Insulin resistance"
        },
        {
            "endOffset": 61208,
            "parents": [],
            "secId": "s0095",
            "sentence": "The greatest difference lies in the C ring in which vamorolone has a CC double bond between carbons 9 and 11 whereas in the more conventional glucocorticoids position 9 is a methylene and position 11 sports a 11-beta hydroxy group.",
            "startOffset": 60977,
            "title": "Discussion"
        },
        {
            "endOffset": 33606,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "In Cohort 1, 3 sentinel subjects were administered vamorolone or placebo in a 2:1 ratio.",
            "startOffset": 33518,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 53510,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "The structure of vamorolone was solved in the non-centrosymmetric spacegroup P212121 with Z\u2019 = 3 (i.e., there are three crystallographically independent molecules in the asymmetric unit).",
            "startOffset": 53323,
            "title": "X-ray structure determination for vamorolone and comparison to glucocorticoids"
        },
        {
            "endOffset": 23762,
            "parents": [],
            "secId": "s0005",
            "sentence": "Research into the relative effects of genomic and non-genomic activities of steroidal hormones and drugs have been complicated by variable cross-reaction with multiple Type 1 receptors, the variable expression of receptors in specific cell types, and cell-specific ligand metabolism.",
            "startOffset": 23479,
            "title": "Introduction"
        },
        {
            "endOffset": 46914,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "Other safety concerns in children include delay of puberty and growth stunting.",
            "startOffset": 46835,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 52030,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "refoffsets": {
                "b0030": {
                    "endOffset": 52029,
                    "startOffset": 52026
                }
            },
            "secId": "s0080",
            "sentence": "A single dose of pharmacological glucocorticoids results in rapid changes in peripheral blood white cell counts, with increased neutrophils, and decreased lymphocytes [6].",
            "startOffset": 51859,
            "title": "Immune suppression"
        },
        {
            "endOffset": 30786,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "After signing informed consent, a total of 286 subjects were screened, of whom 132 subjects met eligibility criteria and qualified for the study.",
            "startOffset": 30641,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 47799,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "First in morning serum cortisol levels were measured in all Phase 1 MAD subjects, at baseline prior to first administration of vamorolone or placebo, 24 h after the first dose (acute suppression), and 24 h after 14 days of daily dosing (chronic suppression) (Fig. 4).",
            "startOffset": 47532,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 28906,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 28905,
                    "startOffset": 28901
                }
            },
            "secId": "s0005",
            "sentence": "This mitotic synchronization activity may extend to regenerative synchronization and reduction of inflammation in tissues, including muscular dystrophy [23].",
            "startOffset": 28749,
            "title": "Introduction"
        },
        {
            "endOffset": 40448,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The most common TEAE was headache (2 subjects, 6%); all other TEAEs occurred in only 1 subject (3%) per group, and included nausea, toothache, vomiting, ALT increased, hepatic enzyme increased, anthralgia, dizziness, and syncope.",
            "startOffset": 40219,
            "title": "Safety"
        },
        {
            "endOffset": 57490,
            "parents": [],
            "secId": "s0095",
            "sentence": "The first-in-human safety data obtained for vamorolone in adult volunteers agrees with and extends the pre-clinical data.",
            "startOffset": 57369,
            "title": "Discussion"
        },
        {
            "endOffset": 63243,
            "parents": [],
            "secId": "s0095",
            "sentence": "This may improve efficacy relative to prednisone and deflazacort.",
            "startOffset": 63178,
            "title": "Discussion"
        },
        {
            "endOffset": 29964,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 29909,
                    "startOffset": 29905
                }
            },
            "secId": "s0005",
            "sentence": "The vamorolone program operates under a venture philanthropy model [24], working with stake holders and governments worldwide.",
            "startOffset": 29838,
            "title": "Introduction"
        },
        {
            "endOffset": 39538,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The most common TEAEs were dizziness and headache, each reported by 2 subjects overall (4%); all other TEAEs were reported by only 1 subject (2%) and included ear pain, nausea, non-cardiac chest pain, and blood bilirubin increased.",
            "startOffset": 39307,
            "title": "Safety"
        },
        {
            "endOffset": 42081,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The H atoms were placed at calculated positions using the instructions AFIX 13, AFIX 23, AFIX 43, AFIX 137 or AFIX 147 with isotropic displacement parameters having values 1.2 or 1.5 Ueq of the attached C or O atoms.",
            "startOffset": 41865,
            "title": "Single crystal X-ray crystallography"
        },
        {
            "endOffset": 43228,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The geometric mean values for CL/F ranged from 1.76 to 2.31 L/hr/kg or 142 to 196 L/hr with no apparent dependence on dose, providing further evidence of linear PK (Table 1).",
            "startOffset": 43054,
            "title": "Pharmacokinetics: Single ascending dose"
        },
        {
            "endOffset": 44945,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Within the variability intrinsic to small groups of subjects (n = 6 per dose group), the geometric mean values for Cmax and AUC (0\u201324) on Days 1 and 14 were not significantly different.",
            "startOffset": 44760,
            "title": "Pharmacokinetics: Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 47372,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "First-in-morning cortisol levels below 3.6 \u00b5g/dL suggest that the adrenal cortex is not able to mount a diurnal cortisol response, and adrenal function is suppressed.",
            "startOffset": 47206,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 41551,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The structure was solved with computer programs CrysAlis PRO, Agilent Technologies, Version 1.171.36.32 (release 02-08-2013 CrysAlis171 .",
            "startOffset": 41414,
            "title": "Single crystal X-ray crystallography"
        },
        {
            "endOffset": 38513,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "Subjects in MAD cohorts 1 to 4 were asked permission to keep any remaining specimens for possible use in future research studies, such as testing for biomarkers, but no human genetic testing was performed on these samples.",
            "startOffset": 38291,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 59700,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 59590,
                    "startOffset": 59586
                }
            },
            "secId": "s0095",
            "sentence": "Consistent with bone findings in pre-clinical models, where prednisone (5 mg/kg/day) induced severe stunting of growth and osteopenia, yet vamorolone (30 mg/kg/day) did not [15], we found no alterations of bone turnover markers at any dose of vamorolone in the adult volunteers (Fig. 5).",
            "startOffset": 59413,
            "title": "Discussion"
        },
        {
            "endOffset": 25432,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 25431,
                    "startOffset": 25426
                },
                "b0030": {
                    "endOffset": 25431,
                    "startOffset": 25426
                }
            },
            "secId": "s0005",
            "sentence": "The glucocorticoid class of hormones and drugs were initially named for their profound effects on glucose metabolism, where they induce insulin resistance within 8 h of an initial dose as low as 0.2 mg/kg [5,6].",
            "startOffset": 25221,
            "title": "Introduction"
        },
        {
            "endOffset": 34817,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "Dose escalation was to be halted if any of the following occurred:",
            "startOffset": 34751,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 48608,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "refoffsets": {
                "b0030": {
                    "endOffset": 48607,
                    "startOffset": 48604
                }
            },
            "secId": "s0065",
            "sentence": "Direct head-to-head comparisons to prednisone-treated subjects were not done in this Phase 1 trial, but approximate comparisons can be done to published literature [6].",
            "startOffset": 48440,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 30287,
            "parents": [],
            "secId": "s0010",
            "sentence": "This clinical trial was a randomized, double-blind, placebo controlled single ascending (SAD) and multiple ascending (MAD) study to evaluate the safety, tolerability, and pharmacokinetics of vamorolone in health adult subjects.",
            "startOffset": 30060,
            "title": "Materials and methods"
        },
        {
            "endOffset": 25221,
            "parents": [],
            "secId": "s0005",
            "sentence": "Indeed, they are considered front-line therapy for both acute and chronic inflammatory conditions.",
            "startOffset": 25123,
            "title": "Introduction"
        },
        {
            "endOffset": 33336,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "Six subjects were assigned to Cohort 6 and were administered a single oral dose of 8.0 mg/kg vamorolone within 30 min of beginning a high fat/high calorie meal.",
            "startOffset": 33176,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 39306,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "In the 0.3 and 3.0 mg/kg vamorolone fasted and the 8.0 mg/kg fed dose groups, 1 subject per group (17%) experienced TEAEs, and no subjects in the 8.0 mg/kg and 20 mg/kg, fasted, dose groups experienced any TEAEs.",
            "startOffset": 39094,
            "title": "Safety"
        },
        {
            "endOffset": 62606,
            "parents": [],
            "secId": "s0095",
            "sentence": "We did not study aspects of efficacy (e.g. serum cytokines) in these Phase 1 studies, as the volunteers were healthy adults, and did not have a pro-inflammatory state.",
            "startOffset": 62439,
            "title": "Discussion"
        },
        {
            "endOffset": 35575,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "The presence of an elevation in alanine aminotransferase (ALT) of greater than or equal to 3 times the upper limit of normal (ULN) in conjunction with an elevation in total bilirubin of greater than or equal to 2 times the ULN in 1 subject within a cohort if considered IP-related by the PI, the subject received vamorolone, and no alternative explanation could be identified.",
            "startOffset": 35199,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 31838,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "One subject, randomized to placebo, terminated the study early to seek care for exacerbation of a previously existing dental condition and did not complete dosing.",
            "startOffset": 31675,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 54698,
            "parents": [],
            "secId": "s0095",
            "sentence": "The pharmacokinetics of vamorolone was well-behaved, with excellent dose proportionality, and little variation between subjects (Figs. 1 and 3).",
            "startOffset": 54554,
            "title": "Discussion"
        },
        {
            "endOffset": 29837,
            "parents": [],
            "secId": "s0005",
            "sentence": "All biomarkers studied were bridged to clinical safety outcomes, including adrenal suppression, insulin resistance, osteopenia, and immune suppression.",
            "startOffset": 29686,
            "title": "Introduction"
        },
        {
            "endOffset": 31493,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "All 54 subjects in the SAD part completed dosing and all study procedures.",
            "startOffset": 31419,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 45268,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The geometric mean values for CL/F ranged from 1.42 to 2.02 L/hr/kg (105 to 168 L/hr) on Day 1 and from 1.26 to 2.15 L/hr/kg (91.7 to 167 L/hr) on Day 14 with no apparent dependence on dose, providing further evidence of linear PK.",
            "startOffset": 45037,
            "title": "Pharmacokinetics: Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 53852,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "All relevant crystallographic data are provided in Supplemental Table 9.",
            "startOffset": 53780,
            "title": "X-ray structure determination for vamorolone and comparison to glucocorticoids"
        },
        {
            "endOffset": 60890,
            "parents": [],
            "secId": "s0095",
            "sentence": "The crystal structures of vamorolone, dexamethasone, and prednisolone share some similarities in conformation (Fig. 6).",
            "startOffset": 60771,
            "title": "Discussion"
        },
        {
            "endOffset": 60976,
            "parents": [],
            "secId": "s0095",
            "sentence": "This is not surprising given the strong similarities in the A, the B and the D rings.",
            "startOffset": 60891,
            "title": "Discussion"
        },
        {
            "endOffset": 47880,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "The two placebo subjects from each dose group were combined into the same panel.",
            "startOffset": 47800,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 57692,
            "parents": [],
            "secId": "s0095",
            "sentence": "Adrenal suppression by vamorolone was monitored by biomarker studies of morning cortisol (diurnal response of the HPA axis) in the MAD, both 24 h after the first dose, and 24 h after 14 days of dosing.",
            "startOffset": 57491,
            "title": "Discussion"
        },
        {
            "endOffset": 53715,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "The absolute configuration was established by anomalous-dispersion effects in diffraction measurements on the crystal, and the Flack and Hooft parameters both refine to \u22120.02(3).",
            "startOffset": 53537,
            "title": "X-ray structure determination for vamorolone and comparison to glucocorticoids"
        },
        {
            "endOffset": 62105,
            "parents": [],
            "secId": "s0095",
            "sentence": "Taken together, the data from these first-in-human Phase 1 clinical trials of vamorolone suggest a significant improvement of safety profiles relative to existing pharmacological glucocorticoid drugs.",
            "startOffset": 61905,
            "title": "Discussion"
        },
        {
            "endOffset": 39093,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "There was no dose-related trend in the incidence or severity of TEAEs; the dose group with the highest number of subjects reporting TEAEs was the 0.1 mg/kg dose group (2 subjects, 33%), and the highest number of TEAEs (3 events) was reported by 1 subject in the 1.0 mg/kg vamorolone dose group.",
            "startOffset": 38799,
            "title": "Safety"
        },
        {
            "endOffset": 37150,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "After completion of all scheduled safety follow-up visits for a given cohort, the SRC reviewed all available PK and safety data (AEs, physical examination findings, ECGs, vital signs, and clinical laboratory tests) in a blinded manner for the completed cohort prior to making a decision to escalate to the next higher dose level.",
            "startOffset": 36821,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 51533,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0075",
            "sentence": "Osteocalcin and CTX1 showed no significant changes in any vamorolone dose group compared to placebo (Fig. 5; Supplemental Tables 3 and 4).",
            "startOffset": 51395,
            "title": "Bone turnover"
        },
        {
            "endOffset": 52373,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0080",
            "sentence": "No significant changes in any white blood cell count were seen in any dose group (Supplemental Fig. 3; Supplemental Tables 58).",
            "startOffset": 52246,
            "title": "Immune suppression"
        },
        {
            "endOffset": 52577,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "There were no severe adverse events observed in any SAD or MAD dose group.",
            "startOffset": 52503,
            "title": "Clinical safety findings in the Phase 1 trials"
        },
        {
            "endOffset": 30386,
            "parents": [],
            "secId": "s0010",
            "sentence": "The study protocol and its amendments were reviewed and approved by an Institutional Review Board.",
            "startOffset": 30288,
            "title": "Materials and methods"
        },
        {
            "endOffset": 58982,
            "parents": [],
            "secId": "s0095",
            "sentence": "Volunteers treated with 9 mg/kg/day and 20 mg/kg/day showed evidence of adrenal suppression, with the failure to mount a diurnal cortisol response for a subset of subjects 24 hrs after the first dose (1 of 6 subjects for 9 mg/kg/day; 4 of 6 for 20 mg/kg/day), and after 14 days of daily dosing (3 of 6 subjects for 9 mg/kg/day; 5 of 5 for 20 mg/kg/day).",
            "startOffset": 58629,
            "title": "Discussion"
        },
        {
            "endOffset": 51836,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0075",
            "sentence": "CTX1 was measured in the same samples and showed no significant changes at any dose level of vamorolone.",
            "startOffset": 51732,
            "title": "Bone turnover"
        },
        {
            "endOffset": 60137,
            "parents": [],
            "secId": "s0095",
            "sentence": "The lack of any changes in bone turnover markers in vamorolone-treated volunteers through 20 mg/kg/day is particularly promising regarding potential improved safety of this dissociative steroid.",
            "startOffset": 59943,
            "title": "Discussion"
        },
        {
            "endOffset": 35744,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "Any other clinical observation that the SRC or PI considered a safety issue such that the higher doses of vamorolone should not be administered to subsequent subjects.",
            "startOffset": 35577,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 36122,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "The duration of dosing in the MAD part was determined based on the PK data from the SAD part.",
            "startOffset": 36029,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 42914,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Log plots of the individual subject Cmax and AUC(inf) were linear.",
            "startOffset": 42848,
            "title": "Pharmacokinetics: Single ascending dose"
        },
        {
            "endOffset": 63796,
            "parents": [],
            "secId": "s0095",
            "sentence": "A key difference in the molecular mechanism of action of vamorolone, a dissociative steroidal drug, vs. traditional glucocorticoid drugs, likely lies in the dimerization of ligand/receptor complexes.",
            "startOffset": 63597,
            "title": "Discussion"
        },
        {
            "endOffset": 26413,
            "parents": [],
            "secId": "s0005",
            "sentence": "Dissociative steroidal drugs dissociate genomic and non-genomic effects, with the goal of retaining anti-inflammatory efficacy while reducing the burden of side effects.",
            "startOffset": 26244,
            "title": "Introduction"
        },
        {
            "endOffset": 35197,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "The presence of the same system (eg, gastrointestinal, cardiac) Grade 3 or greater AE, considered related to IP, in 3 or more subjects in the same cohort, provided the affected subjects received vamorolone.",
            "startOffset": 34991,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 45037,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Consequently, \u201csteady-state\u201d is the same as a single dose for daily dosing with vamorolone.",
            "startOffset": 44946,
            "title": "Pharmacokinetics: Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 43869,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "This indicates that there is an increase in the extent of absorption and decrease in the rate of absorption when vamorolone is administered with this meal.",
            "startOffset": 43714,
            "title": "Pharmacokinetics: Single ascending dose"
        },
        {
            "endOffset": 29425,
            "parents": [],
            "secId": "s0005",
            "sentence": "This was anticipated because the C-ring of our delta 9,11 steroid has a lipophilic double bond rather than the hydrophilic hydroxy or ketone of glucocorticoids.",
            "startOffset": 29265,
            "title": "Introduction"
        },
        {
            "endOffset": 47965,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "No evidence of adrenal suppression was seen in the 1.0 or 3.0 mg/kg/day dose groups.",
            "startOffset": 47881,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 50150,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "refoffsets": {
                "b0025": {
                    "endOffset": 50149,
                    "startOffset": 50143
                },
                "b0135": {
                    "endOffset": 50149,
                    "startOffset": 50143
                }
            },
            "secId": "s0070",
            "sentence": "Prednisone has been shown to lead to detectable insulin resistance within five hours of a single 0.2 mg/kg dose [5,27].",
            "startOffset": 50031,
            "title": "Insulin resistance"
        },
        {
            "endOffset": 37426,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "The dose escalation stopping criteria, as listed above in the SAD section, comprised the halting rules for the MAD part.",
            "startOffset": 37306,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 61459,
            "parents": [],
            "refoffsets": {
                "b0175": {
                    "endOffset": 61458,
                    "startOffset": 61454
                }
            },
            "secId": "s0095",
            "sentence": "Asn-564 is very important for ligand binding and even more for target gene activation and transcription factor repression [35].",
            "startOffset": 61332,
            "title": "Discussion"
        },
        {
            "endOffset": 38290,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "Safety, including criteria for stopping early, was continuously assessed by the Medical Monitor.",
            "startOffset": 38194,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 43713,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "There was a 2.5-fold increase in Cmax, AUC(0-t), and AUC(inf) and an \u223c2-fold increase in Tmax under fed conditions (Table 2).",
            "startOffset": 43588,
            "title": "Pharmacokinetics: Single ascending dose"
        },
        {
            "endOffset": 56333,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 56245,
                    "startOffset": 56238
                },
                "b0080": {
                    "endOffset": 56270,
                    "startOffset": 56260
                },
                "b0085": {
                    "endOffset": 56332,
                    "startOffset": 56328
                },
                "b0090": {
                    "endOffset": 56303,
                    "startOffset": 56299
                },
                "b0095": {
                    "endOffset": 56270,
                    "startOffset": 56260
                },
                "b0115": {
                    "endOffset": 56245,
                    "startOffset": 56238
                },
                "b0120": {
                    "endOffset": 56270,
                    "startOffset": 56260
                }
            },
            "secId": "s0095",
            "sentence": "Vamorolone has shown efficacy similar or superior to prednisone in mouse models of muscular dystrophy [15,23], lung disease [16,19,24], inflammatory bowel disease [18], and multiple sclerosis [17].",
            "startOffset": 56136,
            "title": "Discussion"
        },
        {
            "endOffset": 28366,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 28255,
                    "startOffset": 28251
                }
            },
            "secId": "s0005",
            "sentence": "A pharmacological antagonist for the mineralocorticoid receptor, epleronone, has shown efficacy for improving heart function in Duchenne muscular dystrophy, and many other cardiac disorders [20], suggesting that vamorolone may show benefit for cardiomyopathy in addition to its anti-inflammatory activity.",
            "startOffset": 28061,
            "title": "Introduction"
        },
        {
            "endOffset": 31983,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Two additional subjects, one randomized to placebo and the other to 20 mg/kg vamorolone, discontinued dosing due to AEs but completed the study.",
            "startOffset": 31839,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 47532,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "refoffsets": {
                "b0025": {
                    "endOffset": 47531,
                    "startOffset": 47526
                },
                "b0030": {
                    "endOffset": 47531,
                    "startOffset": 47526
                }
            },
            "secId": "s0065",
            "sentence": "Prednisone causes adrenal suppression at doses of 0.1\u20130.2 mg/kg, both acutely (24 h after first drug dose) and chronically (7 days of daily drug dosing) [5,6].",
            "startOffset": 47373,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 33517,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "Subjects in Cohorts 1 through 5 and 7 were randomized to receive vamorolone or placebo in a 3:1 ratio (6 subjects received vamorolone, and 2 subjects received placebo) sequentially.",
            "startOffset": 33336,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 46256,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "Adrenal suppression is the consequence of a negative feedback loop between high circulating cortisol and pharmacological glucocorticoids and adrenal function, leading to loss of responsiveness of the adrenal cortex to ACTH.",
            "startOffset": 46033,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 29685,
            "parents": [],
            "secId": "s0005",
            "sentence": "We assessed multiple side effects of traditional glucocorticoids using pharmacodynamic biomarkers, both acutely (after a single dose) and chronically (14 daily doses).",
            "startOffset": 29518,
            "title": "Introduction"
        },
        {
            "endOffset": 27528,
            "parents": [],
            "secId": "s0005",
            "sentence": "Cortisol and pharmacological glucocorticoids show high affinity for the mineralocorticoid receptor, similar to its physiological ligand, aldosterone.",
            "startOffset": 27379,
            "title": "Introduction"
        },
        {
            "endOffset": 48816,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "Fleishaker et al. studied doses of 2.5, 5, 10, 20 mg, 40 mg, and 60 mg, with an average weight of subjects of 80 kg.",
            "startOffset": 48700,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 37305,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "Dose escalation in the MAD part was to proceed according to protocol until the MTD was identified.",
            "startOffset": 37207,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 55502,
            "parents": [],
            "secId": "s0095",
            "sentence": "Most glucocorticoids are prescribed as a once-daily regimen, and this is effectively a pulsed dose with little or no drug accumulation between doses; this was observed in the MAD study, where daily dosing showed little or no drug accumulation between doses (Fig. 2).",
            "startOffset": 55236,
            "title": "Discussion"
        },
        {
            "endOffset": 35879,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "The MAD part of the study was initiated after a review of safety and PK data from SAD cohorts 1 to 6.",
            "startOffset": 35778,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 52245,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0080",
            "sentence": "Differential white blood cell counts were studied in all Phase 1 MAD subjects.",
            "startOffset": 52167,
            "title": "Immune suppression"
        },
        {
            "endOffset": 31418,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "In the SAD part, 12 subjects were assigned to placebo, and 6 subjects each were assigned to one of seven vamorolone dose groups.",
            "startOffset": 31290,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 61905,
            "parents": [],
            "secId": "s0095",
            "sentence": "Further, that this important difference is largely because of the structural differences in the C ring of vamorolone.",
            "startOffset": 61788,
            "title": "Discussion"
        },
        {
            "endOffset": 26984,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 26983,
                    "startOffset": 26979
                }
            },
            "secId": "s0005",
            "sentence": "Pre-clinical data has shown that vamorolone has potent binding to the glucocorticoid receptor and anti-inflammatory effects similar to traditional glucocorticoid drugs [15].",
            "startOffset": 26811,
            "title": "Introduction"
        },
        {
            "endOffset": 23224,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 23223,
                    "startOffset": 23220
                }
            },
            "secId": "s0005",
            "sentence": "The modulation of target gene transcription by ligand/receptor steroidal complexes is termed \u2018genomic effects\u2019 (also called transactivation) [1].",
            "startOffset": 23079,
            "title": "Introduction"
        },
        {
            "endOffset": 27205,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 27204,
                    "startOffset": 27197
                },
                "b0080": {
                    "endOffset": 27204,
                    "startOffset": 27197
                },
                "b0085": {
                    "endOffset": 27204,
                    "startOffset": 27197
                },
                "b0090": {
                    "endOffset": 27204,
                    "startOffset": 27197
                },
                "b0095": {
                    "endOffset": 27204,
                    "startOffset": 27197
                }
            },
            "secId": "s0005",
            "sentence": "Testing of multiple mouse models of inflammatory states has shown efficacy similar to prednisolone, and dramatic improvements of side effect profiles, including loss of growth stunting and loss of bone fragility [15\u201319].",
            "startOffset": 26985,
            "title": "Introduction"
        },
        {
            "endOffset": 55708,
            "parents": [],
            "secId": "s0095",
            "sentence": "We are currently carrying out Phase 2a clinical studies in 4 to <7 years Duchenne muscular dystrophy children using a daily dosing regimen (pulsed drug exposure) despite the lack of achieving steady state.",
            "startOffset": 55503,
            "title": "Discussion"
        },
        {
            "endOffset": 34225,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "Once Cohort 5 was completed and safety data had been reviewed, subjects in Cohort 6 were administered a single oral dose of 8.0 mg/kg vamorolone within 30 min of beginning a standard high fat/high calorie meal.",
            "startOffset": 34015,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 41333,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "All reflection intensities were measured at 110(2) K using a SuperNova diffractometer (equipped with Atlas detector) with Cu K\u03b1 radiation (\u03bb = 1.54178 \u00c5) under the program CrysAlisPro (Version 1.171.36.32 Agilent Technologies, 2013).",
            "startOffset": 41100,
            "title": "Single crystal X-ray crystallography"
        },
        {
            "endOffset": 45637,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "This suggests that vamorolone should be administered as a fixed rather than body size-based dose in adults.",
            "startOffset": 45530,
            "title": "Pharmacokinetics: Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 36028,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "In the MAD part, 4 cohorts containing 8 subjects each were randomized to receive vamorolone or placebo, in a 3:1 ratio, once daily (QD) for 14 days.",
            "startOffset": 35880,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 39848,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "One subject (2%) had a moderate TEAE of blood bilirubin increased, which was considered unrelated to study drug.",
            "startOffset": 39736,
            "title": "Safety"
        },
        {
            "endOffset": 31674,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Thirty-one of the 32 subjects in the MAD part completed the study.",
            "startOffset": 31608,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 29517,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here, we report the initial clinical experience with vamorolone in healthy adult volunteers.",
            "startOffset": 29425,
            "title": "Introduction"
        },
        {
            "endOffset": 30038,
            "parents": [],
            "secId": "s0005",
            "sentence": "This effectively de-risks the program, while also encouraging innovation.",
            "startOffset": 29965,
            "title": "Introduction"
        },
        {
            "endOffset": 32684,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The majority of subjects were white (16 subjects, 50%), followed by black (14 subjects, 44%).",
            "startOffset": 32591,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 28586,
            "parents": [],
            "secId": "s0005",
            "sentence": "Vamorolone can not be metabolized by 11\u03b2-Hydroxysteroid dehydrogenase (11BHSD) isoforms, and thus should show greater stability in aldosterone-responsive cells (e.g. not inactivated as cortisol and glucocorticoids are).",
            "startOffset": 28367,
            "title": "Introduction"
        },
        {
            "endOffset": 49537,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "Aligning the dose/response of prednisone vs. vamorolone, 0.25 mg/kg prednisone was equal to 3.0 mg/kg vamorolone (9 \u00b5g/dL cortisol), and 0.75 mg/kg prednisone equal to 9 mg/kg vamorolone (6 \u00b5g/dL cortisol).",
            "startOffset": 49331,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 34751,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "Data unblinding did not occur until after database lock.",
            "startOffset": 34695,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 40546,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "TEAEs were considered possibly related in 2 subjects (6%) and remotely related in 1 subject (3%).",
            "startOffset": 40449,
            "title": "Safety"
        },
        {
            "endOffset": 50909,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0075",
            "sentence": "Bone turnover markers bridged to later bone morbidities include osteocalcin for bone formation, and CTX1 (C-terminal telopeptide of collagen 1) for bone absorption.",
            "startOffset": 50745,
            "title": "Bone turnover"
        },
        {
            "endOffset": 58313,
            "parents": [],
            "secId": "s0095",
            "sentence": "Comparison to vamorolone data 24 h after the initial dose (Fig. 4), showed about 10-fold less suppression of the diurnal cortisol response, with vamorolone responses at 3.0 mg/kg (mean = 9 \u00b5g/dL cortisol), 9 mg/kg (mean = 6 \u00b5g/dL cortisol) and 20 mg/kg (mean = 4 \u00b5g/dL cortisol).",
            "startOffset": 58034,
            "title": "Discussion"
        },
        {
            "endOffset": 64125,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 64124,
                    "startOffset": 64120
                }
            },
            "secId": "s0095",
            "sentence": "The activity of vamorolone is retained with GRdim (dimerization defective mutants) [15].",
            "startOffset": 64037,
            "title": "Discussion"
        },
        {
            "endOffset": 42443,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The initial starting dose for the vamorolone SAD study was chosen based on 10% of the NOAEL in the most sensitive species (mouse) (0.1 mg/kg).",
            "startOffset": 42301,
            "title": "Pharmacokinetics: Single ascending dose"
        },
        {
            "endOffset": 44532,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Although the slopes ranged from 0.827 to 0.898, the deviation from 1.0 may be a consequence of between-subject variability and not indicative of a less than dose-proportional increase in exposure.",
            "startOffset": 44336,
            "title": "Pharmacokinetics: Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 63597,
            "parents": [],
            "refoffsets": {
                "b0100": {
                    "endOffset": 63596,
                    "startOffset": 63586
                },
                "b0180": {
                    "endOffset": 63596,
                    "startOffset": 63586
                },
                "b0185": {
                    "endOffset": 63596,
                    "startOffset": 63586
                }
            },
            "secId": "s0095",
            "sentence": "Vamorolone is a mineralocorticoid antagonist similar in potency to eplerenone, and this may improve both cardiac and skeletal muscle function in DMD [20,36,37].",
            "startOffset": 63437,
            "title": "Discussion"
        },
        {
            "endOffset": 37207,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "Data unblinding did not occur until after database lock.",
            "startOffset": 37151,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 58033,
            "parents": [],
            "secId": "s0095",
            "sentence": "In dose ranging studies of prednisone in adult volunteers (2.5 mg\u201360 mg), evidence for blunting of the diurnal cortisol response 24 h after the first prednisone dose was seen in the 20 mg group (0.25 mg/kg) (mean = 9 \u00b5g/dL cortisol), 40 mg group (0.5 mg/kg) (mean = 7 \u00b5g/dL cortisol), and 60 mg group (0.75 mg/kg) (mean = 9 \u00b5g/dL cortisol).",
            "startOffset": 57693,
            "title": "Discussion"
        },
        {
            "endOffset": 40814,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The remotely related TEAEs were dizziness and syncope, both occurring in the same subject (1.0 mg/kg vamorolone).",
            "startOffset": 40701,
            "title": "Safety"
        },
        {
            "endOffset": 44335,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Log-log plots of the individual subject Cmax and AUC (inf) were linear.",
            "startOffset": 44264,
            "title": "Pharmacokinetics: Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 47205,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "Measurement of first-in-morning cortisol 24 h after the last drug dose indicates whether the drug has suppressed the normal diurnal cortisol response.",
            "startOffset": 47055,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 31607,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "In the MAD part, 8 subjects were randomly assigned to each of four dose groups (2 placebo, 6 drug per dose group).",
            "startOffset": 31493,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 32295,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A total of 54 male subjects between 19 and 64 years of age, with a BMI range of 21.2 to 31.6 kg/m2, participated in the SAD part.",
            "startOffset": 32166,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 29141,
            "parents": [],
            "secId": "s0005",
            "sentence": "Finally, steroidal drugs may alter physicochemical properties of cell membrane systems when integrating and traversing lipid compartments.",
            "startOffset": 29003,
            "title": "Introduction"
        },
        {
            "endOffset": 37595,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "If any of these criteria were met during the 14-day dosing duration in the MAD part, dosing in that cohort was to be halted and no further dose escalation was to occur.",
            "startOffset": 37427,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 42251,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The structural coordinates of the X-ray crystal structure of vamorolone have been deposited in the Cambridge Crystallographic Data Centre, deposition number CCDC 1557034.",
            "startOffset": 42081,
            "title": "Single crystal X-ray crystallography"
        },
        {
            "endOffset": 55986,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 55985,
                    "startOffset": 55978
                },
                "b0115": {
                    "endOffset": 55985,
                    "startOffset": 55978
                },
                "b0120": {
                    "endOffset": 55985,
                    "startOffset": 55978
                }
            },
            "secId": "s0095",
            "sentence": "This decision was based upon the desire to benchmark against daily prednisone and deflazacort in DMD, as well as increasing evidence of a mitotic and regenerative re-synchrony activity of both glucocorticoids and vamorolone that may benefit from a pulsed drug exposure [22\u201324].",
            "startOffset": 55709,
            "title": "Discussion"
        },
        {
            "endOffset": 32740,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Two subjects (6%) were of Hispanic or Latino ethnicity.",
            "startOffset": 32685,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 39735,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Possibly related TEAEs included nausea (1 subject, 2%), dizziness (2 subjects, 4%), and headache (2 subjects, 4%).",
            "startOffset": 39621,
            "title": "Safety"
        },
        {
            "endOffset": 48146,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "At 9.0 mg/kg/day, there was a decline in morning cortisol in all subjects, with 1 subject below the 3.6 \u00b5g/dL after first dose, and 3 of 6 subjects after two weeks of daily dosing.",
            "startOffset": 47966,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 57369,
            "parents": [],
            "secId": "s0095",
            "sentence": "Safety concerns of metabolic derangement (insulin resistance) have not been studied in pre-clinical models to date.",
            "startOffset": 57254,
            "title": "Discussion"
        },
        {
            "endOffset": 54246,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "While there is considerable overlap in structures with both glucocorticoids, the principal structural and molecular difference results from vamorolone\u2019s double bond that orients the C-ring differently than the C-rings of the two comparison glucocorticoids.",
            "startOffset": 53990,
            "title": "X-ray structure determination for vamorolone and comparison to glucocorticoids"
        },
        {
            "endOffset": 51036,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "refoffsets": {
                "b0150": {
                    "endOffset": 51035,
                    "startOffset": 51031
                }
            },
            "secId": "s0075",
            "sentence": "These biomarkers predict phenotypes of osteopenia and used in clinical trials to monitor bone side effects of treatments [30].",
            "startOffset": 50910,
            "title": "Bone turnover"
        },
        {
            "endOffset": 24188,
            "parents": [],
            "secId": "s0005",
            "sentence": "Cortisol shows high affinity binding to both the glucocorticoid receptor (NR3C1) where ligand/receptor complexes dimerize, enter the cell nucleus, and show broad genomic effects in all cells and tissues.",
            "startOffset": 23985,
            "title": "Introduction"
        },
        {
            "endOffset": 25122,
            "parents": [],
            "secId": "s0005",
            "sentence": "The drug class of glucocorticoids, including prednisone, deflazacort, dexamethasone, and fluticasone, have remained among the most prescribed drugs, with about 90 million prescriptions per year in the US (#3 after opioids and thyroxines).",
            "startOffset": 24884,
            "title": "Introduction"
        },
        {
            "endOffset": 44759,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Consistent with the t\u00bd relative to the 24-hour dosing frequency, there was essentially no drug accumulation between doses, as evidenced by essentially superimposable plasma concentrations of day 1 and day 14 PK curves (Fig. 3).",
            "startOffset": 44532,
            "title": "Pharmacokinetics: Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 22709,
            "parents": [],
            "secId": "s0005",
            "sentence": "The largest class of steroidal hormones are those secreted by the adrenal glands targeting Type 1 nuclear hormone receptors, and include glucocorticoids (cortisol), sex steroids (estrogen, progesterone, testosterone), and mineralocorticoids (aldosterone).",
            "startOffset": 22454,
            "title": "Introduction"
        },
        {
            "endOffset": 25883,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 25671,
                    "startOffset": 25668
                },
                "b0045": {
                    "endOffset": 25705,
                    "startOffset": 25702
                },
                "b0050": {
                    "endOffset": 25748,
                    "startOffset": 25744
                },
                "b0055": {
                    "endOffset": 25790,
                    "startOffset": 25786
                }
            },
            "secId": "s0005",
            "sentence": "Others include changes in bone metabolism leading to osteopenia, bone breaks, and avascular necrosis of femoral head [8], mood and psychiatric changes [9], skeletal muscle atrophy and weakness [10], hypertension and renal disturbances [11], and rapid and profound suppression of the HPA axis leading to broad endocrine disturbances.",
            "startOffset": 25551,
            "title": "Introduction"
        },
        {
            "endOffset": 40700,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Possibly related AEs were ALT increased and hepatic enzyme increased, occurring in 1 subject in the 20 mg/kg vamorolone and placebo groups, respectively.",
            "startOffset": 40547,
            "title": "Safety"
        },
        {
            "endOffset": 53536,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "The structure is ordered.",
            "startOffset": 53511,
            "title": "X-ray structure determination for vamorolone and comparison to glucocorticoids"
        },
        {
            "endOffset": 63177,
            "parents": [],
            "secId": "s0095",
            "sentence": "It is important to note that the loss of side effects enables higher dosing of vamorolone relative to standard glucocorticoid drugs.",
            "startOffset": 63045,
            "title": "Discussion"
        },
        {
            "endOffset": 38194,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "Once safety data from additional cohort(s) was assessed, the MTD was defined as the dose level below the dose at which the SRC determined there was an unacceptable risk to subjects.",
            "startOffset": 38013,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 46382,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "Adrenal suppression can be seen both acutely (hours after a single dose of pharmacological glucocorticoids), and chronically.",
            "startOffset": 46257,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 43053,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Although the slope for Cmax was <1.0, that for AUC(inf) was close to 1.0 and indicates a linear or dose-proportional increase in exposure.",
            "startOffset": 42915,
            "title": "Pharmacokinetics: Single ascending dose"
        },
        {
            "endOffset": 22921,
            "parents": [],
            "secId": "s0005",
            "sentence": "These hormones diffuse through cell membranes where they bind cytosolic Type 1 receptors, dimerize, translocate to the nucleus, and regulate gene transcription through binding of target gene regulatory elements.",
            "startOffset": 22710,
            "title": "Introduction"
        },
        {
            "endOffset": 25550,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 25549,
                    "startOffset": 25546
                }
            },
            "secId": "s0005",
            "sentence": "Metabolic disturbance is one of many severe side effects typically seen with chronic use of glucocorticoid drugs [7].",
            "startOffset": 25433,
            "title": "Introduction"
        },
        {
            "endOffset": 34014,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "In Cohorts 2 to 5, and 7, subjects were administered vamorolone or placebo in a 3:1 ratio.",
            "startOffset": 33924,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 40847,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "All TEAEs were mild in severity.",
            "startOffset": 40815,
            "title": "Safety"
        },
        {
            "endOffset": 59413,
            "parents": [],
            "secId": "s0095",
            "sentence": "Thus, both pre-clinical (mouse) and human Phase 1 data suggest that vamorolone shows considerably less adrenal suppression and associated safety concerns compared to glucocorticoids.",
            "startOffset": 59231,
            "title": "Discussion"
        },
        {
            "endOffset": 55235,
            "parents": [],
            "secId": "s0095",
            "sentence": "Despite the poor solubility, oral delivery with a suspension formulation (4% vamorolone by weight) showed excellent bioavailability, with peak serum concentrations at \u223c 3 h. Both the bioavailability and half-life of vamorolone (\u223c3 h) were similar to other glucocorticoids.",
            "startOffset": 54963,
            "title": "Discussion"
        },
        {
            "endOffset": 51394,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0075",
            "sentence": "In the vamorolone Phase 1 trial, serum osteocalcin levels were assayed prior to dosing (Day 1 predose), 8 h after initial dose (Day 1), pre-dose on day 14 of daily dosing, 8 h after the day 14 (last) dose, and during recovery days 15 and 17.",
            "startOffset": 51153,
            "title": "Bone turnover"
        },
        {
            "endOffset": 54553,
            "parents": [],
            "secId": "s0095",
            "sentence": "For clinical safety, no severe adverse events were observed, and the NOAEL in humans was defined as the highest dose tested (20.0 mg/kg/day).",
            "startOffset": 54412,
            "title": "Discussion"
        },
        {
            "endOffset": 56550,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 56549,
                    "startOffset": 56539
                },
                "b0085": {
                    "endOffset": 56549,
                    "startOffset": 56539
                },
                "b0090": {
                    "endOffset": 56549,
                    "startOffset": 56539
                }
            },
            "secId": "s0095",
            "sentence": "These in vivo pre-clinical studies also showed improvement of bone safety profiles of vamorolone when benchmarked against prednisone tested in parallel, including loss of stunting of growth and osteopenia [15,17,18].",
            "startOffset": 56334,
            "title": "Discussion"
        },
        {
            "endOffset": 40218,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "There was no dose-related trend in the incidence or severity of TEAEs.",
            "startOffset": 40148,
            "title": "Safety"
        },
        {
            "endOffset": 45876,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Four safety concerns of traditional glucocorticoid drugs were measured using serum biomarkers; adrenal suppression, bone turnover, insulin resistance, and immune suppression.",
            "startOffset": 45702,
            "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
        },
        {
            "endOffset": 41413,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The same program was used to refine the cell dimensions and for data reduction.",
            "startOffset": 41334,
            "title": "Single crystal X-ray crystallography"
        },
        {
            "endOffset": 48439,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "One subject stopped dosing due to mild elevation of liver enzymes, and his morning cortisol returned to normal levels within a few days of cessation of dosing (Fig. 4).",
            "startOffset": 48271,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 53779,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "The correct chirality on C8/C10/C13/C14/C16/C17 is S/R/S/S/R/R.",
            "startOffset": 53716,
            "title": "X-ray structure determination for vamorolone and comparison to glucocorticoids"
        },
        {
            "endOffset": 27780,
            "parents": [],
            "secId": "s0005",
            "sentence": "Glucocorticoids and aldosterone act as agonists for the mineralocorticoid receptor, and high circulating levels of pharmacological glucocorticoids result in salt imbalance and water weight gain (Cushingoid appearance) via the renin-angiotensin system.",
            "startOffset": 27529,
            "title": "Introduction"
        },
        {
            "endOffset": 32843,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Demographic characteristics were similar across dose groups in both the SAD and MAD parts of the study.",
            "startOffset": 32740,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 33923,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "Following a review of sentinel safety and tolerability data (including reported adverse events [AEs], clinical laboratory tests, vital signs, and electrocardiograms [ECGs]), the remaining 5 subjects were randomized to receive vamorolone or placebo in a 4:1 ratio and dosed no earlier than 48 h after sentinel dosing.",
            "startOffset": 33607,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 61787,
            "parents": [],
            "secId": "s0095",
            "sentence": "We hypothesize that, although vamorolone binds to the glucorticoid receptor, the GR-ligand complex does not forma dimerize and is thus not an efficient GR-mediated activator.",
            "startOffset": 61613,
            "title": "Discussion"
        },
        {
            "endOffset": 50030,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0070",
            "sentence": "Glucocorticoids were originally named as such due to their potent and acute effects on glucose metabolism, where liver and muscle pathways for insulin signaling are rapidly and profoundly affected, creating a state of insulin resistance.",
            "startOffset": 49793,
            "title": "Insulin resistance"
        },
        {
            "endOffset": 52166,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "refoffsets": {
                "b0015": {
                    "endOffset": 52165,
                    "startOffset": 52159
                },
                "b0155": {
                    "endOffset": 52165,
                    "startOffset": 52159
                }
            },
            "secId": "s0080",
            "sentence": "Increases of neutrophils are from release from peripheral tissues, whereas loss of lymphocytes is due to induction of apoptosis [3,31].",
            "startOffset": 52031,
            "title": "Immune suppression"
        },
        {
            "endOffset": 32935,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "In the SAD part of the study, 7 cohorts were to be enrolled.",
            "startOffset": 32875,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 44124,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Daily doses of vamorolone (1.0, 3.0, 9.0 and 20.0 mg/kg/day) were given in the morning in a fasted state, daily for 14 days, and PK determined on day 1 (after single dose) and day 14 (after the 14th dose).",
            "startOffset": 43919,
            "title": "Pharmacokinetics: Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 54411,
            "parents": [],
            "secId": "s0095",
            "sentence": "We studied the response of 86 adult volunteers to vamorolone over a broad dose range (SAD 0.1\u201320.0 mg/kg; MAD 1.0\u201320.0 mg/kg/day 14-day treatment period).",
            "startOffset": 54257,
            "title": "Discussion"
        },
        {
            "endOffset": 61612,
            "parents": [],
            "secId": "s0095",
            "sentence": "Glucocorticoid receptor interactions with glucocorticoids: evaluation by molecular modeling and functional analysis of glucocorticoid receptor mutants).",
            "startOffset": 61460,
            "title": "Discussion"
        },
        {
            "endOffset": 65078,
            "parents": [],
            "secId": "s0100",
            "sentence": "Eric P. Hoffman (design, conduct, oversight, Sponsor, writing); Valerie Riddle (Medical Monitor); Maxime A. Siegler (X-ray crystallography); Daniel Dickerson (Study Director); Miroslav Backonja (Study Director); William G. Kramer (pharmacokinetics, data interpretation); Kanneboyina Nagaraju (biomarker studies); Heather Gordish-Dressman (statistics); Jesse M. Damsker (project management, data interpretation, biomarkers); John M. McCall (medicinal chemistry, X-ray crystallography, manuscript writing).",
            "startOffset": 64574,
            "title": "Author contributions"
        },
        {
            "endOffset": 28748,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 28747,
                    "startOffset": 28740
                },
                "b0110": {
                    "endOffset": 28747,
                    "startOffset": 28740
                }
            },
            "secId": "s0005",
            "sentence": "Another potential mechanism of action of glucocorticoids is via induction of mitotic synchrony in cells, which in turn reduces the pro-inflammatory state [21,22].",
            "startOffset": 28586,
            "title": "Introduction"
        },
        {
            "endOffset": 48699,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "refoffsets": {
                "b0030": {
                    "endOffset": 48635,
                    "startOffset": 48632
                }
            },
            "secId": "s0065",
            "sentence": "Both Fleishaker et al. [6] and we tested serum cortisol 24 h after the first dose of drug.",
            "startOffset": 48609,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 49770,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "Two week prednisone treatment data for morning cortisol was not published.",
            "startOffset": 49696,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 60604,
            "parents": [],
            "secId": "s0095",
            "sentence": "Here, we found no evidence of drug-induced hyperglycemia at any dose of vamorolone, suggesting that insulin resistance was not induced by vamorolone.",
            "startOffset": 60455,
            "title": "Discussion"
        },
        {
            "endOffset": 39887,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "All other TEAEs were mild in severity.",
            "startOffset": 39849,
            "title": "Safety"
        },
        {
            "endOffset": 33175,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "Eight subjects were assigned to each of Cohorts 1 to 5 and 7 and received a single oral dose of vamorolone (planned as 0.1 mg/kg, 0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, 8.0 mg/kg, and 20.0 mg/kg, respectively) or placebo under fasted conditions.",
            "startOffset": 32936,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 62837,
            "parents": [],
            "secId": "s0095",
            "sentence": "First-in-patient studies in 4 to <7 years DMD boys are currently underway and include a 2 weeks MAD study design similar to the Phase 1 MAD study presented here (Phase 2a), and a 6 months Phase 2a extension study for dose finding.",
            "startOffset": 62607,
            "title": "Discussion"
        },
        {
            "endOffset": 63044,
            "parents": [],
            "secId": "s0095",
            "sentence": "Doses planned were chosen based on the pre-clinical and Phase 1 data, and are 0.25, 0.75, 2.0, and 6.0 mg/kg/day, where the 4% suspension formulation is ingested with a glass of full fat milk (food effect).",
            "startOffset": 62838,
            "title": "Discussion"
        },
        {
            "endOffset": 60771,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 60770,
                    "startOffset": 60766
                }
            },
            "secId": "s0095",
            "sentence": "Likewise, we found no evidence of loss of blood lymphocytes in any vamorolone treated subject, consistent with lack of immunosuppression in pre-clinical studies [15].",
            "startOffset": 60605,
            "title": "Discussion"
        },
        {
            "endOffset": 34989,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "The presence of a serious adverse event (SAE) in 1 subject within a cohort who received vamorolone considered by the PI to be related to the investigational product (IP).",
            "startOffset": 34819,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 26243,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 26242,
                    "startOffset": 26238
                }
            },
            "secId": "s0005",
            "sentence": "Increasing evidence has suggested that anti-inflammatory efficacy of glucocorticoid drugs is predominantly via non-genomic effects, whereas side effects are via genomic effects [13].",
            "startOffset": 26061,
            "title": "Introduction"
        },
        {
            "endOffset": 46834,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "One is adrenal crisis (inability to mount a cortisol stress response after trauma, severe illness, or surgery, with ensuring risk for shock and death).",
            "startOffset": 46683,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 31057,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Of these 132 subjects, 86 were randomized, with 54 in the SAD part of the study and 32 in the MAD part.",
            "startOffset": 30954,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 59942,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 59941,
                    "startOffset": 59936
                },
                "b0030": {
                    "endOffset": 59941,
                    "startOffset": 59936
                },
                "b0165": {
                    "endOffset": 59830,
                    "startOffset": 59823
                },
                "b0170": {
                    "endOffset": 59830,
                    "startOffset": 59823
                }
            },
            "secId": "s0095",
            "sentence": "Bone morbidity due to chronic treatment of glucocorticoids are among the chief safety concerns of families and physicians [33,34], and prednisone causes both acute and chronic changes of bone turnover markers at doses of 0.2 mg/kg/day [5,6].",
            "startOffset": 59701,
            "title": "Discussion"
        },
        {
            "endOffset": 64554,
            "parents": [],
            "secId": "s0095",
            "sentence": "Thus, vamorolone dissociates not only GR-dependent safety and efficacy features, but also MR-dependent features as well.",
            "startOffset": 64434,
            "title": "Discussion"
        },
        {
            "endOffset": 27378,
            "parents": [],
            "secId": "s0005",
            "sentence": "In addition to the dissociation of genomic (lost) and transrepression (retained) activities, vamorolone has changed additional sub-activities of traditional glucocorticoids.",
            "startOffset": 27205,
            "title": "Introduction"
        },
        {
            "endOffset": 45529,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "There were no apparent relationships between CL/F and body size, either as body weight or BMI.",
            "startOffset": 45435,
            "title": "Pharmacokinetics: Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 51731,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "refoffsets": {
                "b0075": {
                    "endOffset": 51730,
                    "startOffset": 51726
                }
            },
            "secId": "s0075",
            "sentence": "This suggests that vamorolone has lost the side effect of bone turnover and osteopenia, consistent with published pre-clinical data in mouse models showing no osteopenia or stunting of growth [15].",
            "startOffset": 51534,
            "title": "Bone turnover"
        },
        {
            "endOffset": 24883,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 24882,
                    "startOffset": 24877
                },
                "b0020": {
                    "endOffset": 24882,
                    "startOffset": 24877
                }
            },
            "secId": "s0005",
            "sentence": "Synthetic variants of cortisol were developed as potent anti-inflammatory drugs showing less cross-reactivity for the mineralocorticoid receptor, and less binding to cortisol binding globulin (CBG) thus increasing bioavailability [3,4].",
            "startOffset": 24647,
            "title": "Introduction"
        },
        {
            "endOffset": 40147,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "In the MAD part, overall, a total of 6 subjects (19%) administered vamorolone or placebo experienced a total of 10 TEAEs: 2 subjects each in the 1.0 mg/kg vamorolone, 20 mg/kg vamorolone, and placebo groups, and none in the 3.0 mg/kg and 9.0 mg/kg dose groups.",
            "startOffset": 39887,
            "title": "Safety"
        },
        {
            "endOffset": 41641,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "b0125": {
                    "endOffset": 41640,
                    "startOffset": 41636
                }
            },
            "secId": "s0040",
            "sentence": "NET) (compiled Aug 2, 2013, 16:46:58), SHELXS2014/7, SHELXL2014/7, and SHELXTL v6.10 [25].",
            "startOffset": 41551,
            "title": "Single crystal X-ray crystallography"
        },
        {
            "endOffset": 46682,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "The resulting hormonal imbalance puts patients at increased risk for a series of safety concerns.",
            "startOffset": 46585,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 64433,
            "parents": [],
            "secId": "s0095",
            "sentence": "The reduced ability of vamorolone to dimerize ligand/receptor complexes leads to loss of the GRE-mediated transcriptional activity increasingly associated with side effects profiles, while also changing the mineralocorticoid receptor activity from an agonist (glucocorticoids) to an antagonist (vamorolone).",
            "startOffset": 64126,
            "title": "Discussion"
        },
        {
            "endOffset": 60229,
            "parents": [],
            "secId": "s0095",
            "sentence": "Metabolic derangement and immunosuppression are key safety concerns of glucocorticoid drugs.",
            "startOffset": 60137,
            "title": "Discussion"
        },
        {
            "endOffset": 64036,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 64035,
                    "startOffset": 64025
                },
                "b0075": {
                    "endOffset": 64035,
                    "startOffset": 64025
                },
                "b0095": {
                    "endOffset": 64035,
                    "startOffset": 64025
                }
            },
            "secId": "s0095",
            "sentence": "Vamorolone binds both the glucocorticoid receptor and mineralocorticoid receptors with high affinity and shows drug-dependent translocation of the cytoplasmic receptor to the nucleus, very similar to traditional glucocorticoids [14,15,19].",
            "startOffset": 63797,
            "title": "Discussion"
        },
        {
            "endOffset": 45434,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "As with the SAD, the geometric mean t\u00bd range was somewhat longer at the higher doses, due primarily to vamorolone being quantifiable in plasma for a longer duration.",
            "startOffset": 45269,
            "title": "Pharmacokinetics: Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 46584,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "refoffsets": {
                "b0130": {
                    "endOffset": 46583,
                    "startOffset": 46579
                }
            },
            "secId": "s0065",
            "sentence": "Chronic treatment with glucocorticoids leads to chronic deficiencies in multiple steroidal hormones, including cortisol, testosterone, 17-hydroxyprogesterone, corticosterone, and 11-deoxycortisol [26].",
            "startOffset": 46383,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 39620,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Three subjects (6%) had TEAEs that were considered possibly related to treatment.",
            "startOffset": 39539,
            "title": "Safety"
        },
        {
            "endOffset": 40977,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "With the exception of the AEs related to hepatic enzymes, there were no other meaningful changes in clinical laboratory parameters",
            "startOffset": 40847,
            "title": "Safety"
        },
        {
            "endOffset": 56688,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 56687,
                    "startOffset": 56683
                }
            },
            "secId": "s0095",
            "sentence": "Measures of immune suppression were studied both in vitro and in vivo, where CD4 cells declined with prednisone, but not vamorolone [15].",
            "startOffset": 56551,
            "title": "Discussion"
        },
        {
            "endOffset": 26810,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 26809,
                    "startOffset": 26802
                },
                "b0075": {
                    "endOffset": 26809,
                    "startOffset": 26802
                }
            },
            "secId": "s0005",
            "sentence": "VBP-15 (generic name vamorolone) was developed as a dissociative steroid by synthesizing a series of compounds with a \u03949,11 steroidal scaffold, and testing of cell-based assays for retention of non-genomic anti-inflammatory activity (inhibition of TNF-induced NF\u1d0bB activation; suppression of innate immunity pathways), and loss of genomic activity (GRE-mediated transcriptional reporters) [14,15].",
            "startOffset": 26413,
            "title": "Introduction"
        },
        {
            "endOffset": 29264,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 29263,
                    "startOffset": 29259
                }
            },
            "secId": "s0005",
            "sentence": "Vamorolone has been shown to impart stability to myogenic cell membranes, whereas prednisone de-stabilizes membranes [15].",
            "startOffset": 29142,
            "title": "Introduction"
        },
        {
            "endOffset": 32446,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Five subjects (9%) were of Hispanic or Latino ethnicity.",
            "startOffset": 32390,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 57050,
            "parents": [],
            "secId": "s0095",
            "sentence": "It is important to note that the potent immunosuppression effects of glucocorticoids are considered an aspect of efficacy in certain clinical indications (leukemias, and humoral auto-immunity disorders), but is considered a safety concern when prescribed in most chronic inflammatory conditions such as Duchenne muscular dystrophy, arthritis, asthma and others.",
            "startOffset": 56689,
            "title": "Discussion"
        },
        {
            "endOffset": 32389,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The majority of subjects were white (28 subjects, 52%), followed by black (20 subjects, 37%).",
            "startOffset": 32296,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 61331,
            "parents": [],
            "secId": "s0095",
            "sentence": "This 11-beta hydroxy of dexamethasone and prednisolone has been shown in receptor ligand crystals to interact with Asn564.",
            "startOffset": 61209,
            "title": "Discussion"
        },
        {
            "endOffset": 59230,
            "parents": [],
            "secId": "s0095",
            "sentence": "One subject in the 20 mg/kg/day showed mild elevations of liver enzymes that were believed to be drug-related, and this subject\u2019s dosing was stopped at 10 days; his adrenal function returned to baseline levels when tested five days later (Fig. 4).",
            "startOffset": 58983,
            "title": "Discussion"
        },
        {
            "endOffset": 52721,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "One subject in the 20 mg/kg/day MAD cohort showed mild elevations of liver enzymes that were thought to be drug related, and dosing was halted.",
            "startOffset": 52578,
            "title": "Clinical safety findings in the Phase 1 trials"
        },
        {
            "endOffset": 53242,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "The adrenal suppression seen at the highest vamorolone dose groups was viewed as a reversible pharmacological safety finding by the study director, and not classified as an adverse event.",
            "startOffset": 53055,
            "title": "Clinical safety findings in the Phase 1 trials"
        },
        {
            "endOffset": 24412,
            "parents": [],
            "secId": "s0005",
            "sentence": "Aldosterone is the natural ligand for the mineralocorticoid receptor (NR3C2), where ligand-bound receptor alters sodium balance.",
            "startOffset": 24284,
            "title": "Introduction"
        },
        {
            "endOffset": 44263,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Consistent with the SAD, mean plasma vamorolone concentrations and dose-related PK parameters increased in a dose related manner (Fig. 3).",
            "startOffset": 44125,
            "title": "Pharmacokinetics: Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 50744,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "refoffsets": {
                "b0145": {
                    "endOffset": 50743,
                    "startOffset": 50739
                }
            },
            "secId": "s0075",
            "sentence": "Pharmacological glucocorticoids cause bone side effects including osteopenia and bone fragility [29].",
            "startOffset": 50643,
            "title": "Bone turnover"
        },
        {
            "endOffset": 49330,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "For vamorolone, the dose groups showing decreases in morning cortisol 24 h after the initial dose were 3 mg/kg (9 \u00b5g/dL cortisol), 9 mg/kg (6 \u00b5g/dL cortisol), and 20 mg/kg (4 \u00b5g/dL cortisol).",
            "startOffset": 49139,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 63436,
            "parents": [],
            "secId": "s0095",
            "sentence": "There are additional up-sides regarding possible improved efficacy of vamorolone relative to glucocorticoids.",
            "startOffset": 63327,
            "title": "Discussion"
        },
        {
            "endOffset": 23478,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 23477,
                    "startOffset": 23474
                }
            },
            "secId": "s0005",
            "sentence": "While most physiological responses to steroidal hormones and drugs have been attributed to their broad genomic effects, there is increasing recognition and interest in non-genomic effects where ligand/receptor complexes interact with other proteins [2].",
            "startOffset": 23225,
            "title": "Introduction"
        },
        {
            "endOffset": 38798,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "In the SAD part, overall, six subjects (11%) administered vamorolone experienced a total of 10 treatment-emergent adverse events (TEAEs); no subject in the placebo group experienced any TEAEs.",
            "startOffset": 38606,
            "title": "Safety"
        },
        {
            "endOffset": 30619,
            "parents": [],
            "secId": "s0010",
            "sentence": "It was conducted in accordance with the principles of the Declaration of Helsinki in place at the time of study conduct and in compliance with the International Council on Harmonisation (ICH) E6 Guideline for Good Clinical Practice.",
            "startOffset": 30387,
            "title": "Materials and methods"
        },
        {
            "endOffset": 58628,
            "parents": [],
            "secId": "s0095",
            "sentence": "Using a benchmark of morning cortisol levels < 3.6 \u00b5g/dL as evidence of inability of the HPA axis to mount a diurnal cortisol response (potential adrenal insufficiency), vamorolone showed no evidence of acute (single dose) or chronic (14 doses) adrenal suppression in the 1.0 and 3.0 mg/kg/day MAD groups (Fig. 4).",
            "startOffset": 58314,
            "title": "Discussion"
        },
        {
            "endOffset": 26061,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 26060,
                    "startOffset": 26056
                }
            },
            "secId": "s0005",
            "sentence": "In children chronically treated with glucocorticoids, complaints of families include stunting of growth, delay of puberty, weight gain, mood disturbances and brittle bones [12].",
            "startOffset": 25884,
            "title": "Introduction"
        },
        {
            "endOffset": 43587,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Administration of vamorolone with a high calorie/high fat meal (40 g fat) resulted in an increase in the mean plasma concentrations (Fig. 2).",
            "startOffset": 43446,
            "title": "Pharmacokinetics: Single ascending dose"
        },
        {
            "endOffset": 30953,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Inclusion/exclusion criteria were those considered standard for studies of this type, including requirement for normal liver-related chemistries, lipase, and amylase.",
            "startOffset": 30787,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 36821,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "The planned dose levels for the MAD part were 1.0 mg/kg (Cohort 1), 3.0 mg/kg (Cohort 2), 9.0 mg/kg (Cohort 3), and 20.0 mg/kg (Cohort 4) or until the maximum tolerated dose (MTD) was identified.",
            "startOffset": 36626,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 32166,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The subject in the 20 mg/kg vamorolone dose group who did not complete dosing with vamorolone was excluded from the PK analysis; thus, the MAD PK population consisted of 23 subjects.",
            "startOffset": 31984,
            "title": "Subject recruitment"
        },
        {
            "endOffset": 34694,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0020",
            "sentence": "After completion of all scheduled safety follow-up visits for a given cohort, a Safety Review Committee (SRC), comprised of the Principal Investigator (PI), the Sponsor\u2019s Medical Monitor, and the Sponsor\u2019s pharmacokineticist, reviewed all available PK and safety data (AEs, physical examination findings, ECGs, vital signs, and clinical laboratory tests) in a blinded manner for the completed cohort prior to making a decision to escalate to the next higher dose level.",
            "startOffset": 34225,
            "title": "Single ascending dose (SAD)"
        },
        {
            "endOffset": 56135,
            "parents": [],
            "secId": "s0095",
            "sentence": "Vamorolone is being developed as a replacement for glucocorticoid treatment of Duchenne muscular dystrophy and other chronic inflammatory conditions.",
            "startOffset": 55986,
            "title": "Discussion"
        },
        {
            "endOffset": 54962,
            "parents": [],
            "secId": "s0095",
            "sentence": "Vamorolone bioavailability showed a pronounced food effect, where ingestion of a 40 g fat meal increased bioavailability by 250% (Fig. 2).",
            "startOffset": 54824,
            "title": "Discussion"
        },
        {
            "endOffset": 38012,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "If dose escalation was terminated, the remaining cohorts could be enrolled to evaluate the safety and PK effects of vamorolone for dose levels between the previously tolerated dose and the dose level at which dose escalation was terminated.",
            "startOffset": 37772,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 52948,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "This subject had mild elevations of bilirubin prior to drug dosing, suggesting there may have been a pre-existing liver condition that may have been exacerbated by high doses of vamorolone, as has been reported for prednisone.",
            "startOffset": 52722,
            "title": "Clinical safety findings in the Phase 1 trials"
        },
        {
            "endOffset": 62439,
            "parents": [],
            "secId": "s0095",
            "sentence": "Adrenal suppression was seen at high doses (9.0 and 20.0 mg/kg/day), but this is \u223c1% of the potency of traditional glucocorticoids.",
            "startOffset": 62308,
            "title": "Discussion"
        },
        {
            "endOffset": 47054,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "Adrenal suppression can be measured with first-in-morning serum cortisol, reflective of the endogenous diurnal cortisol peak pre-awakening.",
            "startOffset": 46915,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 51152,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "refoffsets": {
                "b0025": {
                    "endOffset": 51129,
                    "startOffset": 51126
                }
            },
            "secId": "s0075",
            "sentence": "A single dose of prednisone as low as 0.2 mg/kg leads to rapid reductions in osteocalcin [5] (Supplemental Fig. 2).",
            "startOffset": 51037,
            "title": "Bone turnover"
        },
        {
            "endOffset": 48927,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                },
                {
                    "id": "s0060",
                    "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
                }
            ],
            "secId": "s0065",
            "sentence": "Converting this to mg/kg, the prednisone groups were 0.035, 0.07, 0.15, 0.25 mg/kg, 0.5 mg/kg, and 0.75 mg/kg.",
            "startOffset": 48817,
            "title": "Adrenal suppression"
        },
        {
            "endOffset": 60454,
            "parents": [],
            "secId": "s0095",
            "sentence": "Studies of insulin resistance have not been reported in pre-clinical studies of vamorolone.",
            "startOffset": 60363,
            "title": "Discussion"
        },
        {
            "endOffset": 24283,
            "parents": [],
            "secId": "s0005",
            "sentence": "Cortisol also shows high affinity binding (agonism) for the mineralocorticoid receptor (NR3C2).",
            "startOffset": 24188,
            "title": "Introduction"
        },
        {
            "endOffset": 37771,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0015",
                    "title": "Subject recruitment"
                }
            ],
            "secId": "s0025",
            "sentence": "If AEs/SAEs occurred more frequently in subjects treated with vamorolone compared to subjects treated with placebo, the SRC was to determine if dose escalation could continue.",
            "startOffset": 37596,
            "title": "Multiple ascending dose (MAD)"
        },
        {
            "endOffset": 46009,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Biomarkers utilized to monitor these four safety concerns were each bridged to long-term morbidities and changes in quality of life.",
            "startOffset": 45877,
            "title": "Pharmacodynamic safety biomarkers bridged to clinical outcomes"
        }
    ],
    "docId": "S0039128X1830045X",
    "metadata": {
        "asjc": [
            "1303",
            "1308",
            "1310",
            "1312",
            "1605",
            "3004"
        ],
        "authors": [
            {
                "email": "ericphoffman@gmail.com",
                "first": "Eric P.",
                "initial": "E.P.",
                "last": "Hoffman"
            },
            {
                "email": null,
                "first": "Valerie",
                "initial": "V.",
                "last": "Riddle"
            },
            {
                "email": null,
                "first": "Maxime A.",
                "initial": "M.A.",
                "last": "Siegler"
            },
            {
                "email": null,
                "first": "Daniel",
                "initial": "D.",
                "last": "Dickerson"
            },
            {
                "email": null,
                "first": "Miroslav",
                "initial": "M.",
                "last": "Backonja"
            },
            {
                "email": null,
                "first": "William G.",
                "initial": "W.G.",
                "last": "Kramer"
            },
            {
                "email": null,
                "first": "Kanneboyina",
                "initial": "K.",
                "last": "Nagaraju"
            },
            {
                "email": null,
                "first": "Heather",
                "initial": "H.",
                "last": "Gordish-Dressman"
            },
            {
                "email": null,
                "first": "Jesse M.",
                "initial": "J.M.",
                "last": "Damsker"
            },
            {
                "email": null,
                "first": "John M.",
                "initial": "J.M.",
                "last": "McCall"
            }
        ],
        "doi": "10.1016/j.steroids.2018.02.010",
        "firstpage": "43",
        "issn": "0039128X",
        "lastpage": "52",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "CHEM",
            "PHAR"
        ],
        "title": "Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes"
    }
}